

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043904 A1

(51) International Patent Classification⁷: **C07C 217/64**,
C07D 333/56, A61P 25/24, 25/18, 25/06, A61K 31/381,
31/137

(21) International Application Number:
PCT/US2003/031514

(22) International Filing Date: 24 October 2003 (24.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/424,117 5 November 2002 (05.11.2002) US

(71) Applicant (for all designated States except US): **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BOULET, Serge, Louis** [CA/US]; 10813 Windemere Boulevard, Fishers, IN 46038 (US). **FILLA, Sandra, Ann** [US/US]; 1542 Arborwoods Drive, Brownsburg, IN 46112 (US). **GALLAGHER, Peter, Thaddeus** [GB/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB). **HUDZIAK, Kevin, John** [US/US]; 5944 Magnificent Lane, Indianapolis, IN 46234 (US). **JOHANSSON, Anette, Margareta** [SE/US]; 6350 Brokenhurst Road, Indianapolis, IN 46220 (US). **KARANJAWALA, Rushad, E.** [US/US]; 9732 Autumn Way, Zionsville, IN 46077 (US). **MASTERS, John, Joseph** [US/US]; 12047 Flint Stone Court, Fishers, IN 46038 (US). **MATASSA, Victor** [GB/DE]; Graffinity Pharmaceuticals, Im Neuenheimer Feld 519, 69120 Heidelberg (DE). **MATHES, Brian, Michael** [US/US]; 5335 Cotton Bay Drive West, Indianapolis, IN 46254 (US). **RATHMELL, Richard, Edmund** [GB/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB). **WHATTON,**

Maria, Ann [GB/GB]; Eli Lilly and Company Limited, Kingsclere Road, Basingstoke, Hampshire RG21 2XA (GB). **WOLFE, Chad, Nolan** [US/US]; 16096 Tenor Way, Noblesville, IN 46060 (US).

(74) Agents: **WELCH, Lawrence, T.** et al.; Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE,

[Continued on next page]

WO 2004/043904 A1

(54) Title: 3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE



(57) Abstract: There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from C₂-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n where n is 0, 1 or 2, -CF₃, -CN and -CONH₂; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each

of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl; Z is selected from H, OR₃ or I⁻, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl; R₁ and R₂ are each independently H or C₁-C₄ alkyl; with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.



DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY,

CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
— of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- 1 -

3-ARYLOXY/THIO-3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING
SEROTONIN AND NOREPINEPHRINE REUPTAKE

This invention relates to 3-aryloxy/thio-3-substituted propanamines, and to their use in inhibiting serotonin and norepinephrine reuptake.

5

Serotonin (5HT) has been implicated in the aetiology of many disease states and has been found to be of importance in mental illnesses, depression, anxiety, schizophrenia, eating disorders, obsessive compulsive disorder (OCD) and migraine. Indeed many currently used treatments of these disorders are thought to act by modulating serotonergic tone.

10 During the last decade, multiple serotonin receptor subtypes have been characterised. This has led to the realisation that many treatments act *via* the serotonergic system, such as selective serotonin reuptake inhibitor (SSRI) antidepressants which increase serotonin transmission, such as, for example, the hydrochloride salt of fluoxetine.

-15 Drugs that exert their main action on the norepinephrinergic system have been available for some time, however their lack of selectivity made it difficult to determine specific clinical effects produced by a selective action on norepinephrine reuptake. Accumulating evidence indicates that the norepinephrinergic system modulates drive and energy, whereas the serotonergic system modulates mood. Thus norepinephrine appears to play an
20 important role in the disturbances of vegetative function associated with affective, anxiety and cognitive disorders. Atomoxetine hydrochloride is a selective inhibitor of norepinephrine, and is currently marketed for the treatment of attention deficit hyperactivity disorder (ADHD).


25 Norepinephrine and serotonin receptors are known to interact anatomically and pharmacologically. Compounds that affect only serotonin have been shown to exhibit modulatory effects on norepinephrine, pointing toward an important relationship between the two neurotransmitter systems.

30 Duloxetine, (+)-*N*-methyl-3-(1-naphthalenyloxy)-2-thiophenepropanamine hydrochloride, inhibits the reuptake of both norepinephrine and serotonin, and is currently under

- 2 -

development for the treatment of depression and urinary incontinence. The compound duloxetine was disclosed in US Patents 5,023,269 and 4,956,388.

US patent number 4,018,895 describes aryloxyphenyl propanamine compounds including
5 compounds of the formula



Where R is, for example, phenyl, substituted phenyl, tolyl or anisyl. The compounds block the uptake of various physiologically active monoamines including serotonin, norepinephrine and dopamine. Some of the compounds are selective to one of the
10 monoamines and others have multiple activity. The compounds are indicated as psychotropic agents. Some are also antagonists of apomorphine and/or reserpine.

WO 00/02551 describes *inter alia* 3-aryloxy-3-substituted propanamines which are active at the NMDA receptor and serotonin reuptake site.
15

WO 96/09288 describes indole derivatives which are active at the 5HT receptor. The 5-membered ring portion of the indole moiety is further substituted by one of a number of amine functional groups.

20 WO 01/62714 discloses phenylheteroalkylamine derivatives which are inhibitors of nitric oxide synthase. WO 03/011831 discloses heteroarylheteroalkylamine derivatives which are inhibitors of nitric oxide synthase.


WO 02/094262 discloses heteroaryloxy 3-substituted propanamines as serotonin and
25 norepinephrine reuptake inhibitors.

The present invention provides novel 3-aryloxy/thio-3-substituted propanamines which are potent inhibitors of both serotonin and norepinephrine reuptake. Preferred compounds of the present invention exhibit (i) greater potency of inhibition of the serotonin and/or

- 3 -

- norepinephrine transporters, and/or (ii) improved selectivity of inhibition of the serotonin and/or norepinephrine transporters relative to the dopamine transporter, and/or (iii) improved ADME properties (e.g. reduced tendency to act as a substrate and/or inhibitor for the enzyme Cytochrome P450 2D6), and/or (iv) improved acid stability, as compared to known inhibitors of both serotonin and norepinephrine reuptake.

According to the present invention there is provided a compound of formula I:



wherein

A is selected from -O- and -S-;

X is selected from C₂-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n-

where n is 0, 1 or 2, -CF₃, -CN and -CONH₂;

Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl;

Z is selected from H, OR₃ or F, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl;

R₁ and R₂ are each independently H or C₁-C₄ alkyl;

and pharmaceutically acceptable salts thereof,

with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

- 4 -

The compounds of the present invention are potent and (preferably) selective inhibitors of serotonin and norepinephrine reuptake.

5 In one group of compounds according to the present invention, A is -O-.

In another group of compounds according to the present invention, A is -S-.

Preferably, one of R₁ and R₂ is H.


10

R₁ and R₂ may both be H. Alternatively, one of R₁ and R₂ may be H while the other is C₁-C₄ alkyl, for example C₁-C₃ alkyl. Preferably, one of R₁ and R₂ is H and the other is methyl.

15 It will be appreciated that a compound of formula I will possess at least one or, when Z is not H, at least two chiral centres. Where a structural formula does not specify the stereochemistry at one or more chiral centres, it encompasses all possible stereoisomers and all possible mixtures of stereoisomers (including, but not limited to, racemic mixtures) which may result from stereoisomerism at each of the one or more chiral centers.

20


In one embodiment of the present invention, the compound possesses the stereochemistry defined in formula II



25

In another embodiment of the present invention, the compound possesses the stereochemistry defined in formula III

- 5 -



III

In another embodiment of the present invention, Z is H.

5

In another embodiment of the present invention, X is C₂-C₈ alkyl which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂. In this embodiment, X is preferably selected from ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, neopentyl, 3,3-dimethylbutyl and 2-ethylbutyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy and -CF₃. More preferably, X is selected from n-propyl, i-propyl, n-butyl and i-butyl.

15 In another embodiment of the present invention, X is C₂-C₈ alkenyl which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂. In this embodiment, X is preferably 2-methyl-2-propenyl.

20 In another embodiment of the present invention, X is C₄-C₈ cycloalkylalkyl which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂. In this embodiment, X is preferably selected from cyclohexylmethyl and cyclopropylmethyl.

25

In another embodiment of the present invention (when Z is not H), Y is phenyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S-, -CF₃, and -SCF₃. In this embodiment, Y is preferably

-6-

phenyl optionally substituted with up to 2 substituents each independently selected from F, Cl, Br, I, Me, Et, OMe, SMe, -CF₃, and -SCF₃. More preferably, Y is selected from 2-methylphenyl, 2-ethylphenyl, 2-chlorophenyl, 2-bromophenyl, 2-iodophenyl, 3-methylphenyl, 3-methoxyphenyl, 3-chlorophenyl, 3-fluorophenyl, 3-chlorophenyl, 3-trifluoromethylphenyl, 3-methylsulfanylphenyl, 4-methylphenyl, 4-chlorophenyl, 4-trifluoromethylsulfanylphenyl, 4-fluoro-2-methylphenyl, 3,5-dichlorophenyl and 2,4-dichlorophenyl.

In another embodiment of the present invention (when Z is not H), Y is naphthyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano. In this embodiment, Y is preferably unsubstituted naphthyl or naphthyl which is mono-substituted with a substituent selected from halo, C₁-C₄ alkyl and -CF₃. When the naphthyl group is substituted, the substituent is preferably located at the 4-position of the naphthyl ring. The preferred point of attachment of the optionally substituted naphthyl group to the -O- or -S- atom is attachment at the 1 position. More preferably, Y is selected from naphth-1-yl, 4-trifluoromethyl-naphth-1-yl, 4-chloro-naphth-1-yl, 4-fluoro-naphth-1-yl, 4-methyl-naphth-1-yl and 4-bromo-naphth-1-yl.

In another embodiment of the present invention, Y is benzofuranyl, benzothiazolyl, benzoisothiazolyl or indolyl each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl. In this embodiment, Y is preferably benzofuranyl, benzoisothiazolyl or indolyl each of which may be optionally mono-substituted with Me; and when Y is indolyl it may be substituted or further substituted by an N-methyl substituent. In this embodiment, the preferred point of attachment of the group Y to the -O- or -S- atom is attachment at the 4 or 7 position. When Y is N-substituted indolyl, the substituent is preferably Me. More preferably, Y is selected from benzofuran-7-yl, 2-methyl-benzofuran-7-yl, indol-7-yl, N-methyl-indol-7-yl, indol-4-yl, N-methyl-indol-4-yl, benzoisothiazol-7-yl, benzoisothiazol-4-yl, 7-methyl-benzoisothiazol-7-yl.


-7-

In another embodiment of the present invention, Y is benzothienyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano. In this embodiment, Y is preferably benzothienyl optionally substituted with up to 2 substituents each independently selected from halo, C₁-C₄ alkyl, -CF₃ and cyano. In this embodiment, the preferred point of attachment of the group Y to the -O- or -S- atom is attachment at the 4, 5, 6 or 7 position. More preferably, Y is selected from benzothien-4-yl, 5-fluoro-benzothien-4-yl, 7-methyl-benzothien-4-yl, 7-fluoro-benzothien-4-yl, 7-cyano-benzothien-4-yl, 2-fluoro-benzothien-4-yl, 2-bromo-benzothien-4-yl, 3-methyl-benzothien-4-yl, benzothien-5-yl, benzothien-6-yl, 4-trifluoromethyl-benzothien-6-yl, benzothien-7-yl, 6-fluoro-benzothien-7-yl, 6-chloro-benzothien-7-yl, 4-methyl-benzothien-7-yl, 4-bromo-benzothien-7-yl, 4-cyano-benzothien-7-yl, 4-fluoro-benzothien-7-yl, 2-methyl-benzothien-7-yl, 2-cyano-benzothien-7-yl, 2-fluoro-benzothien-7-yl, 2-bromo-benzothien-7-yl, 5-fluoro-benzothien-7-yl, 4-fluoro-3-methyl-benzothien-7-yl and 3-chloro-4-fluoro-benzothien-7-yl.

In another embodiment of the present invention, Y is quinolyl or isoquinolyl each of which may be optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano. In this embodiment, Y is preferably quinolyl or isoquinolyl each of which may be optionally mono-substituted with a halogen atom. In this embodiment, the preferred point of attachment of the group Y to the -O- or -S- atom is attachment at the 5 or 8 position. More preferably, Y is selected from quinol-8-yl, 5-chloro-quinol-8-yl and isoquinol-5-yl.

In another embodiment of the present invention, Y is thienopyridyl which may be optionally substituted with up to 4 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano. In this embodiment, Y is preferably unsubstituted thieno-[3,2-b]pyridyl or unsubstituted thieno-[3,2-c]pyridyl. In this embodiment, the preferred point of attachment of the group Y to the -O- or -S- atom is attachment at the 7 position.

The present invention also provides sub-groups of compounds of formula I or II or III:



5 wherein

A is selected from -O- and -S-;

X is selected from C₂-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n-
 10 where n is 0, 1 or 2, -CF₃, -CN and -CONH₂;


Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano;
 15 and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl;

Z is selected from H, OR₃ or F, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl;

20 R₁ and R₂ are each independently H or C₁-C₄ alkyl;
 and pharmaceutically acceptable salts thereof.

The present invention also provides sub-groups of compounds of formula I or II or III:

-9-



wherein

A is selected from -O- and -S-;

5 X is selected from C₂-C₈ alkyl, C₂-C₈ alkenyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂;


10 Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl;

15 Z is selected from H, OR₃ or F, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl;

R₁ and R₂ are each independently H or C₁-C₄ alkyl;

and pharmaceutically acceptable salts thereof.

20 The present invention also provides sub-groups of compounds of formula I or II or III:



wherein

A is -O-;

-10-

X is selected from C₂-C₈ alkyl, and C₄-C₈ cycloalkylalkyl;


Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl;

Z is H;

R₁ and R₂ are each independently H or C₁-C₄ alkyl;

and pharmaceutically acceptable salts thereof

The present invention also provides sub-groups of compounds of formula I or II or III:



wherein

A is -O-;

X is selected from ethyl, n-propyl, i-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, neopentyl, 3,3-dimethylbutyl, 2-ethylbutyl, cyclohexylmethyl and cyclopropylmethyl;

Y is selected from benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 2 substituents each independently selected from halo, methyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl;


Z is H;

R₁ is H and R₂ is Me;

and pharmaceutically acceptable salts thereof.

The present invention also provides sub-groups of compounds of formula I or II or III:

-11-



wherein

A is -O-;

5 X is selected from n-propyl, i-propyl, n-butyl, i-butyl, and cyclohexylmethyl;

Y is benzothienyl;

Z is H;

R₁ is H and R₂ is Me;

and pharmaceutically acceptable salts thereof.

10

In the present specification the term "C₂-C₈ alkyl" means a monovalent unsubstituted saturated straight-chain or branched-chain hydrocarbon radical having from 2 to 8 carbon atoms.

15 In the present specification the term "C₂-C₈ alkenyl" means a monovalent unsubstituted unsaturated straight-chain or branched-chain hydrocarbon radical having from 2 to 8 carbon atoms.

In the present specification the term "C₃-C₈ cycloalkyl" means a monovalent
20 unsubstituted saturated cyclic hydrocarbon radical having from 3 to 8 carbon atoms.

In the present specification the term "C₄-C₈ cycloalkylalkyl" means a monovalent unsubstituted saturated cyclic hydrocarbon radical having from 3 to 7 carbon atoms linked to the point of substitution by a divalent unsubstituted saturated straight-chain or
25 branched-chain hydrocarbon radical having at least 1 carbon atom.

In the present specification the term "halo" or "halogen" means F, Cl, Br or I.

- 12 -

In the present specification the term "C₁-C₄ alkoxy" means a monovalent unsubstituted saturated straight-chain or branched-chain hydrocarbon radical having from 1 to 4 carbon atoms linked to the point of substitution by an O atom.

- 5 In the present specification the term "phenyl C₁-C₆ alkyl" means a monovalent phenyl radical linked to the point of substitution by a divalent unsubstituted saturated straight-chain or branched chain hydrocarbon radical having from 1 to 6 carbon atoms.

10 In the above definitions, similar terms specifying different numbers of C atoms take an analogous meaning.

In the present specification the term "dihydrobenzothienyl" includes 2,3-dihydrobenzothienyl and 1,3-dihydrobenzothienyl. 2,3-dihydrobenzothienyl is preferred.

- 15 In the present specification the term "benzothiazolyl" includes 1,2-benzothiazolyl and 2,1-benzothiazolyl. 1,2-benzothiazolyl is preferred.

In the present specification the term "naphthyridyl" includes 1,5-, 1,6-, 1,7- and 1,8-naphthyridyl. 1,7- naphthyridyl is preferred.

- 20 In the present specification the term "thienopyridyl" includes thieno-[2,3-b]pyridinyl, thieno-[2,3-c]pyridinyl, thieno-[3,2-c]pyridinyl and thieno-[3,2-b]pyridinyl. Thieno-[3,2-b]pyridinyl and thieno-[3,2-c]pyridinyl are preferred.

- 25 In the present specification the term "benzothienyl" includes benzo[b]thienyl and benzo[c]thienyl. Benzo[b]thienyl is preferred.


In the present specification the term "benzofuranyl" includes 1-benzofuranyl and isobenzofuranyl. 1-benzofuranyl is preferred.

- 30 In the present specification the abbreviation "Ace-Cl" means α -chloroethyl chloroformate.

-13-

In the present specification the abbreviation "PS-DIPEA" means polymer-supported diisopropylethylamine.


The present invention also provides processes for producing a compound of formula I above or a pharmaceutically acceptable salt thereof, which comprises reacting a
5 compound of the formula IV:



10 where A, X, Y and Z are as formula I above, and W is a leaving group, with an amine NR_1R_2 where R_1 and R_2 are as formula I above, optionally followed by the step of forming a pharmaceutically acceptable salt. Examples of suitable leaving groups include halo, mesylate and tosylate, but the nature of the leaving group is not critical. The reaction
15 may be carried out in a sealed vessel with a lower alkyl alcohol as solvent.

15

The present invention also provides a process for producing a compound of formula I above wherein R_2 is H, or a pharmaceutically acceptable salt thereof, which comprises deprotecting a compound of the formula V:




20

where A, X, Y, Z and R_1 are as formula I above, and R_4 is a suitable N-protecting group, optionally followed by the step of forming a pharmaceutically acceptable salt. Examples

-14-


of suitable N-protecting groups will be known to the person skilled in the art and include, for example, benzyl and t-butoxycarbonyl.

The present invention also provides a process for producing a compound of formula I
5 above wherein Z is OH, or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of the formula VI:



10 where A, X and Y are as formula I above with an amine NR_1R_2 where R_1 and R_2 are as formula I above, optionally followed by the step of forming a pharmaceutically acceptable salt.

The present invention also provides a process for producing a compound of formula I
15 above wherein R_1 and R_2 are H, or a pharmaceutically acceptable salt thereof, which comprises reducing a compound of the formula VII:




20 where A, X, Y and Z are as formula I above, optionally followed by the step of forming a pharmaceutically acceptable salt. Examples of suitable reducing agents will be known to the person skilled in the art.

The present invention also provides a process for producing a compound of formula I
25 above wherein R_1 and R_2 are $\text{C}_1\text{--C}_4$ alkyl, or a pharmaceutically acceptable salt thereof,

-15-

which comprises N-protecting a compound of the formula VIII by the introduction of two C₁-C₄ alkyl groups:



5

where A, X, Y and Z are as formula I above, optionally followed by the step of forming a pharmaceutically acceptable salt. Examples of suitable reagents for effecting N-protection by two C₁-C₄ alkyl groups will be known to the person skilled in the art.

- 10 Compounds of the present invention are inhibitors, preferably selective inhibitors, of the reuptake of both serotonin and norepinephrine and as such are useful as pharmaceuticals. They are particularly useful for the treatment of pain.

- For clinical purposes, pain may be divided into two categories: acute pain and persistent
- 15 pain. Acute pain is provoked by noxious stimulation produced by injury and/or disease of skin, deep somatic structures or viscera, or abnormal function of muscle or viscera that does not produce actual tissue damage. On the other hand, persistent pain can be defined as pain that persists beyond the usual course of an acute disease or a reasonable time for an injury to heal or that is associated with a chronic pathologic process that causes
- 20 continuous pain or the pain recurs at intervals for months or years. If pain is still present after a cure should have been achieved, it is considered persistent pain. For the purpose of the present invention, persistent pain can be chronic non-remitting or recurrent. The difference in definition between acute and persistent pain is not merely semantic but has an important clinical relevance. For example, a simple fracture of the wrist usually
- 25 remains painful for a week to 10 days. If the pain is still present beyond the typical course of treatment, it is likely that the patient is developing reflex sympathetic dystrophy, a persistent pain syndrome that requires immediate effective therapy. Early and effective

-16-

intervention potentially prevents the undue disability and suffering, and avoids the potential development of a condition that becomes refractory to therapy.

Acute and chronic pain differ in etiology, mechanisms, pathophysiology, symptomatology, diagnosis, therapy, and physiological responses. In contrast to the transitory nature of acute pain, persistent pain is caused by chronic pathologic processes in somatic structures or viscera, by prolonged and sometimes permanent dysfunction of the peripheral or central nervous system, or both. Also, persistent pain can sometimes be attributed to psychologic mechanisms and/or environmental factors.

Current therapies for persistent pain include opiates, barbiturate-like drugs such as thiopental sodium and surgical procedures such as neurectomy, rhizotomy, cordotomy, and corpectomy.

The compounds of the present invention are indicated in the treatment of persistent pain and references herein to pain are intended to refer to persistent pain.

In addition to the compounds of formula I and processes for the preparation of said compounds, the present invention further provides pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

Further, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical; and a compound of formula I or a pharmaceutically acceptable salt thereof, for use as a selective inhibitor of the reuptake of both serotonin and norepinephrine.

The present compounds and salts may be indicated in the treatment of disorders associated with serotonin and norepinephrine dysfunction in mammals.

The term "serotonin and norepinephrine dysfunction" as used herein refers to a reduction in the amount of serotonin and norepinephrine neurotransmitters within the synaptic cleft

-17-

below that which would be considered to be normal or desirable for a species, or an individual within that species. Thus the phrase "disorders associated with serotonin and norepinephrine dysfunction in mammals" refers to disorders which are associated with a reduction in the amount of serotonin and norepinephrine neurotransmitters within the synaptic cleft below that which would be considered to be normal or desirable for the mammalian species, or an individual within the species, in question. Some examples of disorders currently believed to be associated with reduced levels of serotonin and norepinephrine within the synaptic cleft include depression, OCD, anxiety, memory loss, urinary incontinence (including stress urinary incontinence and urge incontinence), conduct disorders, attention-deficit disorder (including ADHD), obesity, hot flushes/flushes, pain (including inflammatory pain, neuropathic pain, non-neuropathic non-inflammatory pain, persistent pain, persistent pain of inflammatory and/or neuropathic origin, headache and migraine), eating disorders (including bulimia and anorexia nervosa), inflammatory bowel disorders, functional bowel disorders, dyspepsia, chron's disease, ileitis, ischemic bowel disease, ulcerative colitis, gastroesophageal reflux for functional bowel disorders, irritable bowel syndrome, interstitial cystitis, urethral syndrome, gastric motility disorders, substance abuse (including alcoholism, tobacco abuse, smoking cessation, symptoms caused by withdrawal or partial withdrawal from the use of tobacco or nicotine and drug addiction including cocaine abuse), dementia of ageing, senile dementia, Alzheimer's, Parkinsonism, social phobia, disruptive behavior disorders, impulsive control disorders, borderline personality disorder, chronic fatigue syndrome, panic disorders, post-traumatic stress disorder, schizophrenia, gastrointestinal disorders, cardiovascular disorders, emesis, sleep disorders, cognitive disorders, psychotic disorders, brain trauma, premenstrual syndrome or late luteal syndrome, sexual dysfunction (including premature ejaculation and erectile difficulty), autism, mutism and trichotilomania. The compounds of the present invention are particularly suitable for the treatment of pain.

The compounds of the present invention are also indicated for the treatment of disorders which are ameliorated by an increase in the amount of serotonin and norepinephrine neurotransmitters within the synaptic cleft of a mammal above that which would be

-18-

considered to be normal or desirable for the mammalian species, or an individual within the species, in question.

5 The term "treatment" as used herein refers to both curative and prophylactic treatment of disorders associated with norepinephrine dysfunction.

10 The present invention also provides the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for selectively inhibiting the reuptake of serotonin and norepinephrine; the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of disorders associated with serotonin and norepinephrine dysfunction in mammals; the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder selected from those listed above and in particular selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flushes/flushes and pain; and the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disorder selected from depression, urinary incontinence, particularly stress induced urinary incontinence, and more especially, pain.

20 The present invention further provides a compound of formula I for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, for example a disorder selected from those listed above and in particular selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flushes/flushes and pain, especially depression, urinary incontinence, particularly stress induced urinary incontinence, and, more especially, pain.

25

30 Further the present invention provides a method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; a method for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an

-19-

effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; and a method for treating a disorder selected from those listed above and in particular selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flushes/flushes and pain, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof.

The present invention includes the pharmaceutically acceptable salts of the compounds of formula I. Suitable salts include acid addition salts, including salts formed with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example pyruvic, lactobionic, glycolic, oxalic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric, salicylic, o-acetoxybenzoic, or organic sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic, bisethanesulphonic acid or methanesulphonic acid.


In addition to the pharmaceutically acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically acceptable, acid addition salts, or are useful for identification, characterisation or purification.

While all the compounds of the present invention are believed to inhibit the reuptake of serotonin and norepinephrine in mammals there are certain of these compounds which are preferred for such uses. Preferred values for A, X, Y, Z, R₁ and R₂ and substituents for each have been set out above.

Compounds of the present invention may be prepared by conventional organic chemistry techniques as described below.


When Z is H, 1-X-3-aminopropanols can be prepared via the corresponding 3-amino-*N*-methoxy-*N*-methylpropanamide, known as a Weinreb amide, as follows:

-20-



Subjecting a Weinreb amide of *N*-methyl β -alanine appropriately protected at the nitrogen, for example as a *t*-butyl carbamate (Boc) or as a benzyl amine, to an organometallic reagent like an alkyl Grignard or alkyl lithium results in the desired X-substituted ketone. The ketone can be readily reduced to the desired racemic alcohol using standard reducing agents such as sodium borohydride in a protic solvent such as lower order alkyl alcohols.

The Weinreb amides of this invention may be prepared by conventional organic chemistry techniques as exemplified below:




Subjecting a commercial available appropriately *N*-protected β -alanine to sodium hydride followed by methyl iodide results in the *N*-methylated derivative, which then can be converted to the Weinreb amide by reaction with *N*-methyl-*O*-methylhydroxylamine. The Weinreb amides can also be prepared by reacting a 3-bromopropanoyl chloride with *N*-methyl-*O*-methylhydroxylamine to give the Weinreb amide of 3-bromopropanoic acid, which then can be substituted with an appropriately substituted amine to give the desired Weinreb amide.

When Z is H, another preferred route to 1-X-3-aminopropanols is addition of a suitable organometallic reagent to an appropriately *N*-protected aminoaldehyde. Thus an appropriately protected amine can be added to a vinyl aldehyde in a Michael addition

-21-


reaction to give a 3-aminopropanal. This aminoaldehyde can be subjected to (for example) an alkyl Grignard reagent or an alkyl lithium reagent to give the desired 1-alkylpropanol. Selection of other Grignard reagents or organolithium reagents could provide other 1-X-3-aminopropanols.

5



The benzothiophenes of the invention have been made by several routes. Thus a preferred route is by the alkylation of a thiophenol derivative with bromoacetaldehyde diethyl acetal followed by subsequent acid catalysed cyclisation with polyphosphoric acid in chlorobenzene with elimination of ethanol. Subsequent demethylation provided the hydroxybenzothiophene needed for subsequent ether formation.

10



15


Analogous cyclisation of phenylthioacetone derivatives with PPA can be used to synthesise 3-methyl derivatives of benzothiophene methyl ethers.

A further preferred route to substituted benzothiophenes is an iodine catalysed cyclisation of a mercaptopropenoic acid. Thus a benzaldehyde can be condensed with rhodanine and subsequently hydrolysed under basic conditions to a mercaptopropenoic acid. The resultant mercaptopropenoic acid can be cyclised using iodine and then decarboxylated with diazobicycloundecane in dimethylacetamide. Finally boron tribromide in dichloromethane may be used to demethylate the methyl ether to provide the hydroxybenzothiophene.

20


25

-22-




Methods for the synthesis of other Y-OH precursors of use in the present invention (or literature references describing their synthesis) are provided in the experimental section below.

The corresponding ethers and thioethers can generally be prepared as follows:






The propanols can be subjected to *O*-arylation or *S*-arylation reactions. Various *O*-arylation conditions can be used such as the Mitsunobu reaction, wherein roughly equal quantities of the heteroaryl alcohol and the 1-X,3-aminopropanol are stirred at temperatures of between 0 °C and reflux in a polar non protic solvent such as toluene, with a complexing agent such as 1,1'(azodicarbonyl)dipiperidine, or another derivative, and a phosphine ligand such as tributylphosphine. This type of reaction is well known and further combinations of the Mitsunobu reagents can be found in Organic Preparations and Procedures Int., 1996, 28, 2, 165 and references therein. For converting hydroxy to aryl sulfide it is preferred to react the propanol species with Y-SH, (cyanomethyl)trimethylphosphonium iodide (Tetrahedron, 2001, 57, 5451-5454) and diisopropylamine in propionitrile.

-23-




The corresponding protected amines can be readily converted to the corresponding amines by standard methods. For example, trifluoroacetic acid can be used for deprotection of a
 5 *N*-*t*-butoxycarbonyl group and 1-chloroethyl chloroformate in dichloroethane followed by methanol can be used to remove the benzyl group. Finally, resolution of the obtained racemates can be obtained by chiral chromatography.

The “anti” chain hydroxylated propanamines may be prepared using the methodology
 10 outlined below.




The “syn” chain hydroxylated propanamines may be prepared using the methodology
 15 outlined below.

- 24 -




Alternatively, the “syn” chain hydroxylated propanamines may be prepared using the method outlined below.

5




Alternatively, the “syn” and “anti” chain hydroxylated propanamines may be prepared using the intermediates shown below.

-25-




The same chemical transformations may be applied to each intermediate to obtain each of the four stereochemically distinct final products. For example:

5




Starting from the other three intermediates, the same chemistry may be used to obtain the other three final products, i.e.

10




The four intermediates may be synthesized by two different routes. The first route is shown below:

15




The other two intermediates may be obtained using the same chemistry but starting with the compound:




-26-

The second route is shown below:



The other two intermediates may be obtained using the same chemistry but starting with the compound:



5


The preparation of the reagent 4,4-(dimethyl-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-triphenyl phosphonium is described in J. Org. Chem. 1994, 59, 2289. Note however that for converting hydroxy to aryl sulfide it is preferred to react the propanol species with Y-SH, (cyanomethyl)trimethylphosphonium iodide (Tetrahedron, 2001, 57, 5451-5454) and diisopropylamine in propionitrile.

10

The "syn" chain fluorinated propanamines may be prepared using the method outlined below.


15

-27-



The "anti" chain fluorinated propanamines may be prepared using the method outlined below.

5



The following Examples further illustrate the compounds of the present invention and methods for their synthesis.


10

In the following section, there is described the synthesis of precursors and common intermediates for the compounds of the present invention.

-28-


4-Fluoro-2-methoxybenzenethiol

a) 2-Bromo-5-fluoroanisole



- 5 To a suspension of 2-bromo-5-fluorophenol (20.0 g, 104.7 mmol) and potassium carbonate (21.71 g, 157.1 mmol) in acetone (200 mL) was added dimethyl sulphate (10.90 mL, 115.2 mmol). The resulting suspension was allowed to stir at 60°C for 2 h before being allowed to cool and then concentrated *in vacuo*. The residue was dissolved in ether (200 mL) and water (100 mL). The organic phase was washed with aqueous hydrochloric acid (2 N, 50 mL), saturated sodium bicarbonate solution (50 mL) with the resulting organic phase being dried (MgSO₄) and the solvent evaporated *in vacuo* to give a pale yellow oil (21.46 g, 100%). δ_H (300 MHz, CDCl₃) 7.45 (1H, dd, Ar), 6.70-6.55 (2H, m, Ar), 3.90 (3H, s, OCH₃).
- 10

15 b) 4-Fluoro-2-methoxybenzenethiol




- To a suspension of 2-bromo-5-fluoroanisole (2.00 g, 9.755 mmol) and elemental sulphur (0.468 g, 14.632 mmol) in dry THF (50 mL) was slowly added *tert*-butyl lithium in pentane (1.7 M, 12.6 mL, 21.46 mmol) at -78°C. The resulting suspension was allowed to stir at -78°C for 60 mins before being poured onto saturated ammonium chloride solution (80 mL) and product extracted with diethyl ether (100 mL). The organic phase was washed with aqueous hydrochloric acid (2 N, 40 mL), with the resulting organic phase being dried (MgSO₄) and the solvent evaporated *in vacuo* to give a pale yellow oil. This was treated to a pad of silica gel, eluting with hexane:ethyl acetate [95:5] to give a pale yellow oil (1.50 g, 68%). δ_H (300 MHz, CDCl₃) 7.20 (1H, dd, Ar), 6.65-6.55 (2H, d, Ar), 3.90 (3H, s, OCH₃), 3.68 (1H, s, SH).
- 20
- 25

-29-

Similarly prepared was

3-Methoxy-5-trifluoromethylbenzenethiol as a pale yellow oil (14.473g, 100%). δ_{H} (300 MHz, CDCl_3) 7.40-6.90 (3H, m, Ar), 3.87 (1H, s, SH), 3.80 (3H, s, OCH_3).


3-Fluoro-2-methoxybenzaldehyde



To a suspension of 3-fluoro-2-hydroxybenzaldehyde (5.328 g, 38.02 mmol) and potassium carbonate (7.88 g, 57.03 mmol) in acetone (60 mL) was added dimethyl sulphate (3.96 mL, 41.83 mmol). The resulting suspension was stirred at 60°C for 2 h before being allowed to cool and then concentrated *in vacuo*. The residue was dissolved in dichloromethane (100 mL) and water (50 mL). The organic phase was washed with saturated sodium bicarbonate (50 mL) with the resulting organic phase being dried (MgSO₄) and the solvent evaporated *in vacuo* to give a pale yellow oil (6.262 g, 38.02 mmol, 100%). δ_{H} (300 MHz, CDCl_3) 10.40 (1H, s, CHO), 7.60 (1H, d, Ar), 7.30 (1H, m, Ar), 7.10 (1H, m, Ar), 4.10 (3H, s, OCH_3).

5-Methoxy-2-methylbenzaldehyde

a) 4-Bromo-3-(1,3-dioxolan-2-yl)phenyl methyl ether




A solution of 2-bromo-5-methoxybenzaldehyde (10.00 g, 46.5 mmol) in toluene (600 mL), ethanediol (3.88 mL, 69.8 mmol) and *para*-toluene sulphonic acid (50 mg) were heated under Dean-Stark conditions for 24 h. After this time the reaction was allowed to cool to room temperature before being washed with saturated aqueous sodium hydrogen carbonate (2 x 150 mL). The organic phase was dried (MgSO₄) and the solvent removed *in vacuo* to give a colourless oil (12.6 g, 100%); R_f = 0.23 in hexane:ethyl acetate [10:1];

- 30 -

δ_H (300 MHz, $CDCl_3$) 7.42 (1H, d, Ar), 7.25 (1H, d, Ar), 6.75 (1H, dd, Ar), 6.03 (1H, s, CHO), 4.20-4.01 (4H, m, 2 x CH_2), 3.80 (3H, s, OCH_3).

b) 3-(1,3-Dioxolan-2-yl)-4-methylphenyl methyl ether




5

n-Butyl lithium in hexane (17.07 mL, 1.42 M, 25.1 mmol) was added dropwise at $-78^\circ C$ to a stirred solution of 4-bromo-3-(1,3-dioxolan-2-yl)phenyl methyl ether (5.00 g, 19.3 mmol), in dry THF (60 mL). The resulting solution was allowed to stir at $-78^\circ C$ for 30 mins before being quenched with iodomethane (2.40 mL, 38.6 mmol). The resulting solution was stirred at $-78^\circ C$ for a further 20 mins before being quenched with saturated aqueous ammonium chloride solution (60 mL). The organic phase was dried ($MgSO_4$) and the solvent evaporated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with hexane:ethyl acetate [10:1] to give a pale yellow oil (3.07 g, 82%); $R_f = 0.40$ in hexane:ethyl acetate [10:1]; δ_H (300 MHz, $CDCl_3$) 7.20-6.99 (2H, m, Ar), 6.75 (1H, dd, Ar), 5.92 (1H, s, CH), 4.20-4.01 (4H, m, 2 x CH_2), 3.80 (3H, s, OCH_3), 2.32 (3H, s, CH_3).

10

15

c) 5-Methoxy-2-methylbenzaldehyde




20

25


A solution of 2-(2-methyl-5-methoxyphenyl)-1,3-dioxalane (7.28 g, 37.5 mmol) in THF (1200 mL) and HCl (5%, 50 mL) was stirred at room temperature for 48 h. After this time the reaction was diluted with diethyl ether (100 mL) and washed with brine. The organic phase was dried ($MgSO_4$) and the solvent evaporated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with hexane:ethyl acetate [95:5] to give a pale yellow oil (4.93 g, 88%); $R_f = 0.31$ in hexane:ethyl acetate [10:1]; δ_H (300 MHz, $CDCl_3$) 10.28 (1H, s, CHO), 7.35-6.99 (3H, m, Ar), 3.82 (3H, s, OCH_3), 2.62 (3H, s, CH_3).

-31-

1-[(5-Fluoro-2-methoxyphenyl)thio]-2-propanone

tert-Butyl lithium in pentane (6.30 mL, 10.7 mmol) was added dropwise at -78°C over 35
5 mins to a stirred suspension of 2-bromo-4-fluoroanisole (1.00 g, 4.87 mmol) and
elemental sulfur (234 mg, 7.31 mmol) in dry THF (10 mL). The resulting yellow solution
was stirred at -78°C for 15 mins before 1-chloro-2-propanone (894 mg, 9.74 mmol) was
added. The resulting solution was allowed to stir at -78°C for 1 hr before being quenched
with NH₄Cl (sat., 20 mL). The organic phase was extracted and dried (MgSO₄) and the
10 solvent removed *in vacuo*. The residue was purified by flash chromatography eluting
silica gel with hexane:ethyl acetate [4:1] to yield a colourless oil (1.03 g, 98%) which
slowly solidified on standing; *R*_f = 0.34 in hexane:ethyl acetate [4:1]; δ_H (300 MHz,
CDCl₃) 7.08-6.98 (1H, dd, Ar), 6.95-6.82 (1H, m, Ar), 6.80-6.71 (1H, dd, Ar), 3.91 (3H,
s, OCH₃), 3.75 (2H, s, CH₂), 2.30 (3H, s, CH₃).

15

1-[(2-Fluoro-5-methoxyphenyl)thio]-2-propanone

To a solution of 2,2,6,6-tetramethylpiperidine (8.03 mL, 47.6 mmol) in THF (20 mL) at -
78°C was added a solution of 2.5 M *n*-butyllithium in hexanes (19.04 mL, 47.6 mmol).
20 After stirring for 30 minutes at -78°C a solution of 4-fluoroanisole (5 g, 39.7 mmol) in
THF (10 mL) was added dropwise. After a further 30 minutes elemental sulphur (1.78 g,
55.5 mmol) was added and stirred until almost all of the sulphur has disappeared. 1-
chloro-2-propanone (3.79 mL, 47.6 mmol) was then added and the solution warmed to
room temperature over 2 hours. The reaction was quenched by pouring into saturated
25 ammonium chloride (50 mL) and extraction with diethyl ether (2 x 50 mL). The
combined organic extracts were dried (MgSO₄) and the solvent removed *in vacuo* to give


- 32 -

a brown oil which was purified by flash chromatography with a gradient of 0-5% diethyl ether in hexane to give the title compound (1.96 g, 23%); δ_{H} (300 MHz, CDCl_3) 7.02-6.86 (2H, m, ArH), 6.80-6.71 (1H, m, ArH), 3.78 (3H, s, OCH_3), 3.68 (2H, s, CH_2) and 2.29 (3H, s, CH_3).

5

1-Benzothien-7-yl methyl ether

a) 1-[(2,2-Diethoxyethyl)thio]-2-methoxybenzene



To a suspension of 2-methoxybenzenethiol (10 g, 71.4 mmol) and potassium carbonate (20 g, 143 mmol) in dry *N,N*-dimethylformamide (100 mL) was added dropwise over 20 mins a solution of bromoacetaldehyde diethyl acetal (10.3 mL, 71.4 mmol) in dry *N,N*-dimethylformamide (50 mL). The resulting suspension was allowed to stir at room temperature for 45 mins before being diluted with water (500 mL) and extracted with hexane (200 mL). The organic phase was further extracted with brine (4 x 100 mL), with the resulting organic phase being dried (MgSO_4) and the solvent removed *in vacuo* to give a pale yellow oil (18.6 g) which was ca 95% pure. This material was further purified by flash chromatography eluting silica gel with hexane:ether [10:1] to give a colourless oil (18 g, 98%). δ_{H} (300 MHz, CDCl_3) 7.34 (1H, d, Ar), 7.2 (1H, m, Ar), 6.92-6.80 (2H, m, Ar), 4.62 (1H, t, $J = 7$ Hz, $\text{CH}(\text{OEt})_2$), 3.85 (3H, s, OCH_3), 3.70-3.42 (4H, m, OCH_2CH_3), 3.10 (2H, d, $J = 7$ Hz, SCH_2), 1.12 (6H, t, $J = 7$ Hz, OCH_2CH_3).

15

20

Similarly prepared were

1-[(2,2-Diethoxyethyl)thio]-4-fluoro-2-methoxybenzene as a colourless oil (0.828 g, 3.018 mmol, 46%). δ_{H} (300 MHz, CDCl_3) 7.38 (1H, dd, Ar), 6.90 (2H, m, Ar), 4.62 (1H, t, $J = 7$ Hz, $\text{CH}(\text{OEt})_2$), 3.85 (3H, s, OCH_3), 3.70-3.45 (4H, m, OCH_2CH_3), 3.00 (2H, d, $J = 7$ Hz, SCH_2), 1.18 (6H, t, $J = 7$ Hz, OCH_2CH_3).

25


1-[(2,2-Diethoxyethyl)thio]-3-methoxy-5-trifluoromethylbenzene as a pale orange oil (6.87 g, 21.18 mmol, 34%). δ_{H} (300 MHz, CDCl_3) 7.20 (1H, s, Ar), 7.00 (1H, s, Ar), 6.90

30

-33-

(1H, s, Ar), 4.65 (1H, t, $J = 7$ Hz, $\text{CH}(\text{OEt})_2$), 3.80 (3H, s, OCH_3), 3.70-3.50 (4H, m, OCH_2CH_3), 3.15 (2H, d, $J = 7$ Hz, SCH_2), 1.20 (6H, t, $J = 7$ Hz, OCH_2CH_3).

b) 1-Benzothien-7-yl methyl ether



5 A solution of 1-[(2,2-diethoxyethyl)thio]-2-methoxybenzene (18 g, 70.3 mmol) in dry chlorobenzene (100 mL) was added slowly to a stirred solution of polyphosphoric acid (50g) in dry chlorobenzene (300 mL) at 145°C. After addition was complete the resulting black solution was stirred at 155°C for a further 18 hrs. After this time the reaction was
10 allowed to cool to room temperature before being filtered through a pad of CELITE™, the solid cake was washed with dichloromethane (200 mL) and the combined organic extracts were concentrated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with hexane:ethyl acetate [95:5] to give a pale yellow oil (8.7 g, 75%); δ_{H} (300 MHz, CDCl_3) 7.45-7.29 (4H, m, Ar), 6.75 (1H, d, Ar), 4.00 (3H, s, OCH_3).


15 Similarly prepared were

5-Fluoro-1-benzothien-7-yl methyl ether as a pale yellow oil (0.132 g, 0.724 mmol, 24%); δ_{H} (300 MHz, CDCl_3) 7.50 (1H, d, Ar), 7.28 (1H, d, Ar), 7.10 (1H, d, Ar), 6.58
20 (1H, d, Ar), 4.00 (3H, s, OCH_3).

4-Trifluoromethyl-1-benzothien-6-yl methyl ether as a yellow oil (2.832 g, 12.19 mmol, 58%); δ_{H} (300 MHz, CDCl_3) 7.50-7.35 (3H, m, Ar), 7.28 (1H, s, Ar), 3.90 (3H, s, OCH_3).

25 **4-Fluoro-7-methoxy-1-benzothiophene**

a) 5-(2-Fluoro-5-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one



-34-

To a suspension of 2-fluoro-5-methoxybenzaldehyde (5.00 g, 32.46 mmol) and rhodanine (4.31 g, 32.46 mmol) in dry toluene (1000 mL) was added ammonium acetate (50 mg) and acetic acid (2 mL). The resulting suspension was allowed to stir at 120°C for 12 h under Dean-Stark apparatus before being allowed to cool and filtered. Resultant solid was washed with hexane and allowed to dry *in vacuo* to give an orange crystalline solid (8.00 g, 91%); δ_{H} (300 MHz, CDCl_3) 7.50 (1H, s, $\text{CH}=\text{C}$); 7.31 (1H, t, Ar), 7.20-7.11 (1H, m, Ar), 6.95-6.89 (1H, m, Ar), 3.80 (3H, s, OCH_3).


Similarly prepared were

10

5-(3-Fluoro-2-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one as an orange solid (7.942 g, 78%). δ_{H} (300 MHz, CDCl_3) 7.82 (1H, s, ArCHCR_2), 7.30-7.10 (3H, m, Ar), 4.05 (3H, s, OCH_3).

15 5-(2-Methyl-5-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one as an orange crystalline solid (8.00 g, 91%); δ_{H} (300 MHz, CDCl_3) 7.80 (1H, s, Ar), 7.29-7.10 (1H, m, Ar), 6.95-6.84 (2H, m, Ar and $\text{CH}=\text{C}$), 3.83 (3H, s, OCH_3), 2.37 (3H, s, CH_3).

b) (2Z)-3-(2-Fluoro-5-methoxyphenyl)-2-mercapto-2-propenoic acid



20

5-(2-Fluoro-5-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one (8.00g, 9.7 mmol) was added in one portion to 25% w/v sodium hydroxide solution (40 mL). This was allowed stir at reflux for 1 h. After this time the reaction was allowed to cool to room temperature and poured onto water (50 mL). This was washed with dichloromethane (50 mL), and the aqueous layer acidified to pH 2 with aqueous hydrochloric acid (2 N, 50 mL) to give a white suspension. Product was extracted with ether (2 x 60 mL), dried (MgSO_4) and solvent removed *in vacuo* to give a white solid (6.71 g, 100%); δ_{H} (300 MHz, CD_3OD) 7.85 (1H, s, Ar), 7.46-7.35 (1H, m, Ar), 7.11 (1H, t, Ar), 7.01-6.75 (2H, m, $\text{CH}=\text{C}$, and SH), 3.80 (3H, s, OCH_3).

25


- 35 -

Similarly prepared were

(2Z)-3-(3-Fluoro-2-methoxyphenyl)-2-mercapto-2-propenoic acid as a solid (1.596 g, 94%); δ_H (300 MHz, $CDCl_3$) 8.12 (1H, s, ArCHCR₂), 7.60 (1H, d, Ar), 7.15-7.00 (2H, m, Ar), 4.55 (1H, s, SH), 3.98 (3H, s, OCH₃).

(2Z)-3-(2-Methyl-5-methoxyphenyl)-2-mercapto-2-propenoic acid as a white solid (6.71 g, 100%); δ_H (300 MHz, $CDCl_3$) 8.00 (1H, s, CH=C), 7.30-7.09 (2H, m, Ar), 6.88-6.78 (1H, m, Ar), 3.80 (3H, s, OCH₃), 2.25 (3H, s, CH₃).

c) 4-Fluoro-7-methoxy-1-benzothiophene-2-carboxylic acid




(2Z)-3-(2-Fluoro-5-methoxyphenyl)-2-mercapto-2-propenoic acid (1.00 g, 4.38 mmol) was added in one portion to a solution of iodine (1.66 g, 6.56 mmol) in dimethoxyethane (10 mL). This was heated in the microwave with 300W at 160°C for 10 mins. After this time the reaction was allowed to cool to room temperature and poured onto saturated sodium metabisulphite (200 mL) and ether (400 mL). Ether layer was separated and product extracted with aqueous sodium hydroxide (2 N, 2 x 100 mL). This was then acidified to pH 2 with aqueous hydrochloric acid (2 N, 250 mL), and product extracted with ether (2 x 150 mL). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to give a white solid (580 mg, 30%); δ_H (300 MHz, CD_3OD) 8.00 (1H, s, Ar), 7.30-7.19 (1H, m, Ar), 7.10-7.00 (1H, m, Ar), 3.95 (3H, s, OCH₃).

Similarly prepared was

4-Methyl-7-methoxy-1-benzothiophene-2-carboxylic acid as white solid (580 mg, 30%); δ_H (300 MHz, $CDCl_3$) 8.20 (1H, s, Ar), 7.12 (1H, d, Ar), 6.75 (1H, d, Ar), 3.99 (3H, s, OCH₃), 2.59 (3H, s, CH₃).

-36-

d) 4-Fluoro-7-methoxy-1-benzothiophene



4-Fluoro-7-methoxy-1-benzothiophene-2-carboxylic acid (2.00 g, 8.84 mmol) was added
5 in one portion to DBU (8 mL) and dimethyl acetamide (10 mL). This was heated in the
microwave with 300W at 200°C for 1 h. The reaction mixture was allowed to cool and
poured onto water (100 mL). Product was extracted with hexane (2 x 100 mL), washed
with aqueous hydrochloric acid (2 N, 50 mL), aqueous sodium hydroxide (2 N, 50 mL),
and the combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. The
10 residue was purified by flash chromatography eluting silica gel with hexane:ethyl acetate
[96:4] to give an oil (1.12 g, 70%); δ_{H} (300 MHz, CDCl₃) 7.4 (2H, s, Ar), 6.9 (1H, t, Ar),
6.60 (1H, dd, Ar), 3.91 (3H, s, OCH₃).

Similarly prepared was

15

4-Methyl-7-methoxy-1-benzothiophene as an oil (1.12 g, 70%); δ_{H} (300 MHz, CDCl₃)
7.46-7.32 (2H, m, Ar), 7.10 (1H, d, Ar), 6.66 (1H, d, Ar), 3.98 (3H, s, OCH₃), 2.52 (3H, s,
CH₃).

20 **5-Fluoro-4-methoxy-1-benzothiophene**


(2Z)-3-(3-Fluoro-2-methoxyphenyl)-2-mercapto-2-propenoic acid (4.865 g, 21.315 mmol)
was added in one portion to a solution of iodine (8.255 g, 31.973 mmol) in
dimethoxyethane (30 mL). This was heated in the microwave with 300W at 120°C for 25
25 mins. After this time the reaction was allowed to cool to room temperature and poured
onto saturated sodium metabisulphite (200 mL) and ether (400 mL). Ether layer was
separated and product extracted with aqueous sodium hydroxide (2 N, 2 x 100 mL). This
was then acidified to pH 2 with aqueous hydrochloric acid (2 N, 250 mL), and product
extracted with ether (2 x 150 mL). The combined organic extracts were dried (MgSO₄)

-37-

and concentrated *in vacuo* to give a tan coloured solid (3.240 g, 14.322 mmol, 67%). Which was used without further purification in the next step. 5-Fluoro-4-methoxy-1-benzothiophene-2-carboxylic acid (0.883 g, 3.903 mmol) was added in one portion to DBU (2.04 mL, 13.661 mmol) and dimethyl acetamide (10 mL). This was heated in the
5 microwave with 300W at 200 °C for 1 h. Reaction was allowed to cool and poured onto water (100 mL). Product was extracted with hexane (2x100 mL), washed with aqueous hydrochloric acid (2 N, 50 mL), aqueous sodium hydroxide (2 N, 50 mL), and the combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. The residue
10 was purified by flash chromatography eluting silica gel with hexane:ethyl acetate [96:4] to give a pale yellow oil (0.167 g, 23%); δ_H (300 MHz, CDCl₃) 7.60-6.80 (4H, m, Ar), 4.10 (3H, s, OCH₃).

7-Fluoro-4-methoxy-1-benzothiophene


a) 2-(5-Fluoro-2-methoxyphenyl)-2-hydroxy-*N,N*-dimethylethanethioamide




15

To a solution of lithium diisopropylamide, 2M in THF/*n*-heptane (210 mL, 583 mmol) was added THF (100 mL) and the solution cooled to -78°C under nitrogen. This was then added dropwise over 1 h to a solution of the 5-fluoro-2-methoxybenzaldehyde (50 g, 0.32 mmol) and *N,N*-dimethylthioformamide (34.7 g, 389 mmol) in dry THF (200 mL). This
20 was warmed to -5°C and quenched with water (400 mL). The solution was filtered and washed with diethyl ether, the aqueous layer was extracted with ether (1 L). The combined organic layers were washed with water (500 mL), dried (MgSO₄) and the solvent removed *in vacuo* to give a crystalline suspension in oil. This was triturated in ether and filtered to give a crystalline solid (21.8 g, 28%); δ_H (300 MHz, CDCl₃) 7.16-6.81 (3H, m, ArH), 5.81-5.75 (1H, m, CHOH), 5.31-5.22 (1H, m, OH), 4.89 (3H, s, OCH₃), 3.50 (3H, s, N(CH₃)₂) and 3.08 (3H, s, N(CH₃)₂).
25

-38-

b) *N*-(7-Fluoro-4-methoxy-1-benzothien-2-yl)-*N,N*-dimethylamine


A solution of 2-(5-fluoro-2-methoxyphenyl)-2-hydroxy-*N,N*-dimethylethanethioamide (0.5 g, 2.1 mmol) in Eaton's reagent (5 mL) were combined and heated rapidly to 60°C and left for 1 h. After cooling to room temperature over 2 hours the mixture was dropwise addition into prechilled aqueous sodium hydroxide (2 N, 16.25 mL) with constant stirring. This solution was then extracted with methyl *tert*-butyl ether (5 x 20 mL) and the combined organic extracts were dried (MgSO₄) and the solvent removed *in vacuo* to give a yellow solid. This was purified by flash chromatography with a gradient of 0-2% diethyl ether in hexane and gave 0.2 g of yellow solid containing an impurity, this was triturated with hexane to leave a colourless solid (0.155 g, 34%) of the title compound; δ_H (300 MHz, CDCl₃) 6.70-6.52 (2H, m, ArH), 6.12-6.10 (1H, m, ArH) 3.90 (3H, s, OCH₃) and 3.2 (6H, s, N(CH₃)₂), $M+H = 226.1$.

c) 7-Fluoro-4-methoxy-1-benzothiophen-2(3*H*)-one

To a solution of *N*-(7-fluoro-4-methoxy-1-benzothien-2-yl)-*N,N*-dimethylamine (1.73 g, 7.7 mmol) in THF (25 mL) was added aqueous hydrochloric acid (1 N, 25 mL) and this was heated to 80°C for 3 h. After cooling to room temperature then extracted with ether (100 mL), dried (MgSO₄) and the solvent evaporated *in vacuo* to give a yellow solid. The residue was purified by flash chromatography in 5% ethyl acetate in hexane to give (1.3 g, 84%) of the title compound; δ_H (300 MHz, CHCl₃) 6.97-6.87 (1H, m, ArH), 6.62-6.55 (1H, m, ArH), 3.91 (2H, s, CH₂) and 3.85 (3H, s, OCH₃).

d) 7-Fluoro-4-methoxy-1-benzothiophene


- 39 -



To a solution of 7-fluoro-4-methoxy-1-benzothiophen-2(3*H*)-one (1.06, 5.4 mmol) in dichloromethane (10 mL) at 0°C was added slowly a solution of diisobutylaluminium hydride in dichloromethane (1 M, 8.04 mL, 8.0 mmol). After 30 mins the reaction was quenched by careful addition of aqueous hydrochloric acid (6 N, 25 mL). The mixture was concentrated to remove the dichloromethane, the aqueous residue was then stirred at 35°C for 2 h. The aqueous solution was extracted with diethyl ether (3 x 50 mL), washed with aqueous sodium hydroxide (2 N, 50 mL), brine (50 mL) then dried (MgSO₄) and the solvent evaporated *in vacuo* to give the title compound (0.86 g, 87%) as a purple oil; δ_{H} 7.44-7.38 (1H, m, ArH), 7.36-7.24 (1H, m, ArH), 6.88-6.80 (1H, m, ArH), 6.57-6.49 (1H, m, ArH) and 3.82 (3H, s, OCH₃).

7-Fluoro-4-methoxy-1-benzothiophene

a) 2,3-Difluoro-6-methoxybenzaldehyde




A solution of lithium diisopropylamide, 2M in THF/n-heptane (171 mL, 341 mmol) was further diluted with dry THF (250 mL) and cooled under nitrogen to -75°C. 3,4-Difluoroanisole (46.8 g, 325 mmol) in dry THF (100 mL) was added dropwise and the mixture stirred at -75°C for 1h. Dry *N,N*-dimethylformamide (27.6 mL, 358 mmol) was added dropwise and the mixture stirred for 10 mins at -70°C. Acetic acid (30 mL) and water (400 mL) were added, warming the temperature to 10°C. Extracted into diethyl ether (2 x 300 mL). Combined extracts were washed with water (250 mL), aqueous hydrochloric acid (0.2 N, 400 mL) and brine (2 x 250 mL), dried (MgSO₄) and the solvent evaporated *in vacuo* to give a red/orange oil which crystallised. Purification was by recrystallisation from diethyl ether/petroleum ether 40-60 to give (53.0g, 95%) of solid;

- 40 -

δ_H (300 MHz, $CDCl_3$) 10.40 (1H, s, CHO), 7.37 (1H, q, ArH), 6.71 (1H, m, ArH), and 3.93 (3H, s, OCH_3).


b) Methyl 7-fluoro-4-methoxy-1-benzothiophene-2-carboxylate



5 Methyl thioglycolate (28.8 mL, 320 mmol) was added under nitrogen to a solution of triethylamine (86.6 mL) in dry *N,N*-dimethylformamide (220 mL) at 80°C. Stirred at 100°C for 15 mins. A solution of 2,3-difluoro-6-methoxybenzaldehyde (55.1 g, 320 mmol) in *N,N*-dimethylformamide (80mL) was added and the mixture heated at 130°C for
10 3h. Allowed to cool then poured onto ice-water (2L). The resulting yellow solid was filtered, washing with water (2 x 200 mL). Dried under vacuum over phosphorus pentoxide at room temperature overnight to give the title compound (67.2g, 87%); δ_H (300 MHz, $CDCl_3$) 8.20 (1H, d, ArH), 7.06 (1H, t, ArH), 6.68 (1H, m, ArH) and 3.99 (6H, s, OCH_3 and CO_2CH_3).

15

c) 7-Fluoro-4-methoxy-1-benzothiophene-2-carboxylic acid




A mixture of methyl 7-fluoro-4-methoxy-1-benzothiophene-2-carboxylate (67.2 g, 280 mmol), sodium hydroxide (45 g, 1.12 mol), methanol (800 mL) and water (400 mL) were
20 stirred at ambient overnight. The methanol was evaporated and the mixture cooled to 0°C. Acidified with concentrated hydrochloric acid and stirred for 20 mins. The yellow solid was filtered, washing with water (3 x 100 mL). Dried under vacuum at 45°C overnight, over phosphorus pentoxide to give the title compound (61.4 g, 97%); δ_H (300 MHz, d_6 -DMSO) 8.10 (1H, d, ArH) 7.44 (1H, t, ArH) 7.00 (1H, m, ArH) and 4.02 (3H, s, OCH_3).

25

d) 7-Fluoro-4-methoxy-1-benzothiophene

- 41 -




A mixture of 7-fluoro-4-methoxy-1-benzothiophene-2-carboxylic acid (61.4 g, 271 mmol) and copper powder (22.4 g, 352 mmol) in quinoline (500 mL) was heated at 190°C for 1h. Cooled to ambient and poured onto aqueous hydrochloric acid (2 N, 750 mL).

- 5 Stirred with ethyl acetate (500 mL) for 15 minutes. Filtered through Celite, washing with ethyl acetate. The aqueous layer was extracted into ethyl acetate and the combined organic layers were washed with aqueous hydrochloric acid (2 N, 500 mL), water (500 mL), brine (500 mL), dried over MgSO₄ and evaporated *in vacuo*. Purified by column chromatography, eluting silica gel with *iso*-hexane/diethyl ether 0-5% to give the product
- 10 as a brown oil which crystallised to give the title compound (41.3g, 84%); δ_H (300 MHz, CDCl₃) 7.51 (1H, m, ArH), 7.38 (1H, d, ArH), 6.98 (1H, t, ArH), 6.65 (1H, dd, ArH) and 3.92 (3H, s, OCH₃).

3-Chloro-4-fluoro-7-methoxy-1-benzothiophene

- 15 a) (2E)-3-(2-Fluoro-5-methoxyphenyl)-2-propenoic acid




- A solution of 2-fluoro-5-methoxybenzaldehyde (10.00 g, 64.9 mmol), malonic acid (13.4 g, 128.8 mmol), piperidine (2.00 mL) and pyridine (100 mL) was heated to 110°C for 2h. After this time the solvent was removed *in vacuo* and the residue taken up in ethyl acetate
- 20 and washed with aqueous hydrochloric acid (2N, 100 mL). The organic solvent was dried (MgSO₄) and the solvent evaporated *in vacuo*. The solid was recrystallised from hot ethanol to give a white solid (12.2 g, 95%); δ_H (300 MHz, DMSO) 7.60 (1H, d, J 7Hz, CH=C), 7.31-7.28 (1H, m, Ar), 7.20 (1H, t, Ar), 7.07-6.97 (1H, m, Ar), 6.62 (1H, d, J 8Hz, CH=CH), 3.80 (3H, s, OCH₃).

25


- 42 -

b) Methyl 3-chloro-4-fluoro-7-methoxy-1-benzothiophene-2-carboxylate




Thionyl chloride (3.7 mL, 50.8 mmol) was added to a stirred solution of (2E)-3-(2-fluoro-5-methoxyphenyl)-2-propenoic acid (2.5 g, 12.7 mmol) and pyridine (100 μ L). The resulting yellow suspension was stirred at 120°C for 2 h before being allowed to cool to room temperature. The mixture was diluted with dichloromethane (50 mL) and concentrated *in vacuo*. The resulting yellow solid was taken up in methanol (100 mL) and heated to 70°C for 1 hr. After this time the solvent was removed *in vacuo* to leave a white solid (984 mg, 28%); δ_H (300 MHz, $CDCl_3$) 7.09-6.98 (1H, m, Ar), 6.80-6.71 (1H, dd, Ar), 3.98 (6H, s, OCH_3 and CO_2CH_3).

c) 3-Chloro-4-fluoro-7-methoxy-1-benzothiophene-2-carboxylic acid.



Methyl 3-chloro-4-fluoro-7-methoxy-1-benzothiophene-2-carboxylate (2.00 g, 7.29 mmol) was suspended in THF:H₂O [10:1] and lithium hydroxide (260 mg) added, the resulting suspension was heated to 40°C for 1 h. After cooling to room temperature the mixture was extracted with diethyl ether (50 mL) and the aqueous phase acidified to pH 2 and the solid collected by filtration and vacuum dried to give a white solid (1.09 g, 58%); δ_H (300 MHz, DMSO) 7.32-7.20 (1H, m, Ar), 7.15-7.05 (1H, dd, Ar), 3.98 (3H, s, OCH_3).


d) 3-Chloro-4-fluoro-7-methoxy-1-benzothiophene.



-43-

A mixture of 3-chloro-4-fluoro-7-methoxy-1-benzothiophene-2-carboxylic acid (1.09 g, 4.19 mmol) and diazobicycloundecane (DBU) (2 mL) in dimethylacetamide (15 mL) was heated in a sealed vessel in a microwave (300W, 100%) for 1 h. After cooling to room temperature the mixture was diluted with diethyl ether (100 mL) and washed with brine (2
5 x 100 mL). The organic phase was dried (MgSO₄) and the solvent removed *in vacuo*. The residue was purified by flash chromatography eluting silica gel with hexane:diethyl ether [10:1] to yield a white solid (520mg, 57%); δ_H (300 MHz, CDCl₃) 7.24 (1H, s, Ar), 7.05-6.92 (1H, m, Ar), 6.70-6.60 (1H, dd, Ar), 3.96 (3H, s, OCH₃).

10 **4-Fluoro-7-methoxy-3-methyl-1-benzothiophene**




1-[(5-fluoro-2-methoxyphenyl)thio]acetone (1.00 g, 4.67 mmol) was added to a stirred solution of polyphosphoric acid (2.00 g) and chlorobenzene (70 mL). The resulting solution was stirred rapidly at 160°C for 18 h. After this time the solution was allowed to
15 cool to room temperature and washed with water (50 mL). The aqueous phase was extracted with dichloromethane (3 x 30 mL) and the combined organic extracts dried (MgSO₄). The solvent was removed *in vacuo* and the residue purified by flash chromatography eluting silica gel with hexane:ethyl acetate [10:1] to give a pale yellow oil (700 mg, 76%); R_f = 0.72 in hexane:ether [10:1]; δ_H (300 MHz, CDCl₃) 7.44-7.20
20 (1H, m, Ar), 6.99-6.82 (1H, m, Ar), 6.62-6.55 (1H, dd, Ar), 3.95 (3H, s, OCH₃), 2.56 (3H, s, CH₃).

Similarly prepared was

25 **7-Fluoro-4-methoxy-3-methyl-benzothiophene** as an oil (1.43 g, 91%); δ_H (300 MHz, CDCl₃) 7.22 (1H, s, ArH), 6.89-6.81 (1H, m, ArH), 6.59-6.52 (1H, m, ArH), 3.81 (3H, s, OCH₃) and 2.56 (3H, s, CH₃).

2-Fluoro-7-methoxy-1-benzothiophene

- 44 -




A solution of 1-benzothiophen-7-yl methyl ether (230 mg, 1.40 mmol) in dry THF (5 mL) was added dropwise to a freshly prepared solution of 2,2,6,6-tetramethyl-lithio-piperidine (1.68 mmol) in THF (10 mL) at -78°C . The resulting solution was stirred at this temperature for 30 mins before perchloryl fluoride gas was condensed into the reaction. After the strong exotherm had stopped the mixture was allowed to stir at -78°C for a further 30 mins. After this time the reaction was quenched with NH_4Cl (sat, 20 mL) and diluted with diethyl ether. The organic phase was dried (MgSO_4) and the solvent removed *in vacuo*. The residue was purified by flash chromatography eluting silica gel with hexane to yield a colourless oil (128 mg, 50%); δ_{H} (300 MHz, CDCl_3) 7.32-7.20 (2H, m, Ar), 6.80-6.62 (2H, m, Ar), 3.95 (3H, s, OCH_3).

Similarly prepared was

2-Fluoro-4-methoxy-1-benzothiophene as a colourless oil (420 mg, 48%); δ_{H} (300 MHz, CDCl_3) 7.32-7.20 (2H, m, Ar), 6.80-6.62 (2H, m, Ar), 3.95 (3H, s, OCH_3).

7-Methoxy-1-benzothiophene-2-carbonitrile




To a solution of 1-benzothiophen-7-yl methyl ether (1 g, 6.1 mmol) in THF (12 mL) at -78°C was added a solution of 2.5 M n-butyllithium in hexanes (2.9 mL, 7.3 mmol). After stirring for 1.5 hr this solution was added dropwise to a solution of tosyl cyanide (1.66 g, 9.1 mmol) in THF (8 mL), this was left stirring at -78°C for 0.5 hr and then warmed to room temperature. After 16 h this was poured onto ice-water and extracted with dichloromethane (3 x 50 mL). The combined organic extracts were washed with water, dried (MgSO_4) and the solvent removed *in vacuo* to give an oil. This was purified by flash chromatography with a gradient of 0-30% ethyl acetate in hexane to give the title

- 45 -

compound (0.31 g, 27%); δ_H (300 MHz, $CDCl_3$) 7.79 (1H, s, 3-ArH), 7.46-7.38 (1H, m, 4-ArH), 7.37-7.31 (1H, m, 5-ArH), 6.88-6.82 (1H, m, 6-ArH) and 3.94 (3H, s, OCH_3). Starting material 1-benzothien-7-yl methyl ether was recovered from the reaction (0.56 g, 56%); δ_H (300 MHz, $CDCl_3$) 7.45-7.29 (4H, m, ArH), 6.75 (1H, m, ArH), 4.00 (3H, s, OCH_3).


7-Methoxy-1-benzothiophene-2-carbonitrile

a) 2-Iodo-7-methoxy-1-benzothiophene



- 10 In a 4 L mechanically stirred reactor, a solution of 1-benzothien-7-yl methyl ether (105 g, 0.64 mol) in anhydrous THF (2 L) is cooled down to $-74^\circ C$. *n*-Butyl lithium in hexane is added (2.5 N, 285 mL, 0.71 mol) within 45 min, keeping temperature below $-70^\circ C$. The mixture is stirred 30 min at $-78^\circ C$ and a solution of iodine (179 g, 0.70 mol) in anhydrous THF (1L) is added within 1 h, keeping temperature below $-70^\circ C$. After addition, the
- 15 mixture is allowed to come up to room temperature over 2 h and brine (500 mL) is added. The layers are roughly separated and the organic layer is partially evaporated. Additional brine (200 mL) is added to the residual aqueous layer (mixed with some THF). After decantation, the organic and aqueous layers are separated. The aqueous layer is extracted with ethyl acetate (500 mL). The organic layers are pooled, washed with aqueous sodium
- 20 thiosulphate, dried ($MgSO_4$) and the solvent evaporated *in vacuo* to give the crude iodo derivative (173.6 g, 93%) The solid is recrystallized from isopropanol (150 mL) to give pure compound (145.5g, 88%); δ_H (600 MHz, $CDCl_3$) 7.51 (s, 1 H), 7.32 (d(br), $J=7.89$ Hz, 1 H), 7.26 (t, $J=7.89$ Hz, 1 H), 6.72 (d(br), $J=7.89$ Hz, 1 H), 3.97 (s, 3 H).


25 b) 7-Methoxy-1-benzothiophene-2-carbonitrile



-46-

A solution of 2-iodo-7-methoxy-1-benzothiophene (10.0g, 0.35 mol), copper (1) cyanide (6.17 g, 0.68 mol) and anhydrous *N,N*-dimethylformamide (40 mL) are warmed to 130°C. After 2.5 h at 130°C no starting material is detectable as measured by HPLC at 220 nm. The reaction is cooled to 40°C and a solution 25% v/v ethylenediamine in water (30 mL) and toluene (20 mL) are added. The mixture is stirred to room temperature. Additional toluene (30 mL) is added and the heterogeneous mixture is filtered. The layers of the mother liquors are separated and the aqueous layer is extracted with toluene (3 x 50 mL). The combined organic extracts were washed with water (2 x 50 mL), dried (MgSO₄) and the solvent evaporated *in vacuo* to give the title compound (5.78 g, 88%), which was used without further purification; δ_H (300 MHz, CDCl₃) 7.79 (1H, s, 3-ArH), 7.46-7.38 (1H, m, 4-ArH), 7.37-7.31 (1H, m, 5-ArH), 6.88-6.82 (1H, m, 6-ArH) and 3.94 (3H, s, OCH₃).

4-Methoxy-1-benzothiophene-2-carbonitrile




(Ref: Cheutin et al.; C.R.Hebd.Seances Acad.Sci; 261; 1965; 705.) A solution of 4-methoxy-1-benzothiophene-2-carboxylic acid (1.19g, 5.7 mmol) in pyridine (25 mL) at 0°C was treated with methanesulfonyl chloride (0.49 mL, 6.3 mmol) keeping the temperature at 0°C, stirring was continued for 2 h. Ammonia gas was then bubbled through the mixture for 5 minutes, followed by nitrogen for 10 mins. The reaction mixture was then treated with a large excess of mesyl chloride (4.43 mL, 57 mmol) and stirred for 16 h at room temperature. The solvent evaporated *in vacuo* to give a brown residue which was purified by flash chromatography with 10% ethyl acetate in hexane to give a colourless solid (800 mg, 74%); δ_H (300 MHz, CDCl₃) 8.00 (1H, s, 3-ArH), 7.48-7.35 (2H, m, ArH), 6.80-6.77 (1H, m, ArH) and 3.92 (3H, s, OCH₃).

4-Fluoro-7-methoxy-1-benzothiophene-2-carbonitrile


a) 4-Fluoro-7-methoxy-1-benzothiophene-2-carboxamide

- 47 -




A solution of 4-fluoro-7-methoxy-1-benzothiophene-2-carboxylic acid (1.5 g, 6.6 mmol) in thionyl chloride (4 mL) was heated to 50°C for 30 minutes, then the solvent removed *in vacuo*. The residue was taken up in dichloromethane (60 mL) and methanol (0.5 mL) and then added to a solution of concentrated ammonium hydroxide (40 mL) and dichloromethane (40 mL) at 5°C. After 10 min the solution was warmed to room temperature and stirred for 2 h. The dichloromethane was evaporated *in vacuo* and the solid filtered to give a pale brown solid (0.75 g, 51%); δ_H (300 MHz, D_4 -Methanol) 7.95 (1H, s, 3-ArH), 7.02-6.92 (1H, m, ArH), 6.83-6.77 (1H, m, ArH), 3.89 (3H, s, OCH₃) and 3.23-3.28 (2H, m, CONH₂).

b) 4-Fluoro-7-methoxy-1-benzothiophene-2-carbonitrile



A solution of 4-fluoro-7-methoxy-1-benzothiophene-2-carboxamide (0.756 g, 3.3 mmol) in phosphorus oxychloride (6.2 mL, 6.6 mmol) was refluxed for 3 h then cooled and the solvent evaporated *in vacuo* to give the title compound. Purified by flash chromatography with a gradient of 0-30% ethyl acetate in *iso*-hexane to give a colourless solid (0.635 g, 91%); δ_H (300 MHz, CDCl₃) 7.95 (1H, s, 3-ArH), 7.10-7.01 (1H, m, ArH), 6.85-6.77 (1H, m, ArH) and 3.98 (3H, s, OCH₃).

4-Cyano-7-methoxy benzo[b]thiophene.



-48-


To a stirred solution of 4-bromo-7-methoxy benzo[b]thiophene (1.05 g, 4.32 mmol, 1 equiv.) in dry DMF (40 mL) was added copper(I)cyanide (3.885 g, 43.4 mmol, 10 equiv.) and the reaction mixture was heated at 150°C overnight. The reaction mixture was cooled to ~120 °C and then solid iron(III)chloride (1.58 g, 9.74 mmol) was added followed by 1
5 N HCl (CAUTION: HCN evolution – perform in a well vented hood!) The reaction mixture was heated at ~100°C for 2 hr before cooling to room temperature. Water, brine, and ethyl acetate were added and the layers were separated. The organic layer was washed with brine (3 times), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude residue thus obtained was purified via
10 medium pressure liquid chromatography eluting with 10% ethyl acetate/90% hexanes to afford the title compound (564 mg, 69%) as a colorless solid; δ_H (400 MHz, $CDCl_3$) 4.06 (3H, s), 6.81 (1H, d, $J = 8$ Hz), 7.56 (1H, d, $J = 6$ Hz), 7.65 (1H, d, $J = 6$ Hz), 7.71 (1H, d, $J = 8$ Hz).

Ref: (J. Chem. Soc. Perkin Trans 1 1983, 2973).

15


6-Methoxy-1-benzothiophene-2-carbonitrile

a) *O*-(2-Formyl-5-methoxyphenyl) dimethylthiocarbamate




A solution of *N,N*-dimethylcarbamoyl chloride (4.46 g, 35.7 mmol) in THF (20 mL) was
20 added over 15 minutes to a stirred cooled (0°C), solution of 2-hydroxy-4-methoxybenzaldehyde (5 g, 32.9 mmol) and potassium hydroxide (2 g, 35.7 mmol) in water (25 mL) such that the temperature did not rise above 10°C. The mixture was stirred for 10 minutes at room temperature then extracted with ethyl acetate (3 x 50 mL), the combined organic layers were washed successively with 2M sodium hydroxide (100 mL),
25 2N hydrochloric acid (100 mL), brine (100 mL) then dried ($MgSO_4$) and the solvent removed *in vacuo* to give a yellow solid (6.8 g, 86%) which was used without further purification; δ_H (300 MHz, $CDCl_3$) 7.88-7.80 (1H, m, ArH), 7.95-7.85 (1H, m, ArH), 6.65-6.60 (1H, m, ArH), 3.88 (3H, s, OCH_3), 3.46 (3H, s, $N(CH_3)_2$) and 3.40 (3H, s, $N(CH_3)_2$).

-49-

b) *S*-(2-Formyl-5-methoxyphenyl) dimethylthiocarbamate

A pre-warmed solution of *O*-(2-formyl-5-methoxyphenyl) dimethylthiocarbamate (2 g, 8.3 mmol) in diphenyl ether (4 mL) was added to diphenyl ether (36 mL) at 230°C. The mixture was heated at 230°C for 1.5 h. The reaction mixture was loaded neat onto flash chromatography column and solvent eluted with *iso*-hexane. Product eluted with a gradient of 0-30% ethyl acetate in *iso*-hexane. Further purified by flash chromatography with a gradient of 0-20% ethyl acetate in dichloromethane, followed by triturating with *iso*-hexane gave a solid which was recrystallised from ethyl acetate hexane to give the title compound (1.21 g, 61%); δ_H (300 MHz, $CDCl_3$) 8.04-7.95 (1H, m, ArH), 7.09-6.99 (2H, m, ArH), 3.89 (3H, s, OCH_3), 3.16 (3H, br. s, $N(CH_3)_2$) and 3.02 (3H, br. s, $N(CH_3)_2$).

c) 6-Methoxy-1-benzothiophene-2-carbonitrile




(Ref: Gallagher, T; Pardoe, D.A.; Porter, R.A.; Tetrahedron Lett.; 2000, 41(28), 5415 - 5418.) To a solution of *S*-(2-formyl-5-methoxyphenyl) dimethylthiocarbamate (1.08 g, 4.5 mmol) in water (4 mL) and methanol (8 mL) was added sodium hydroxide (199 mg, 4.9 mmol), this was heated to reflux for 16 hours. The reaction was cooled to room temperature and chloroacetonitrile (0.28 mL, 4.5 mmol) was added in one portion and the mixture stirred at room temperature for 1 hour. The methanol was removed *in vacuo*, and water (10 mL) added. The aqueous layer was extracted with diethyl ether (3 x 20 mL), dried ($MgSO_4$) and the solvent removed *in vacuo*. The residue was purified by flash chromatography with a gradient of 0-30% ethyl acetate in *iso*-hexane to give the title compound as a colourless solid (390 mg, 46%); δ_H (300 MHz, $CDCl_3$) 7.80-7.70 (1H, m,

- 50 -

ArH), 7.29 (2H, m, ArH), 7.11-7.01 (1H, m, ArH) and 3.85 (3H, s, OCH₃). M+23 = 212.0. $\nu_{\max}/\text{cm}^{-1}$ [film] 2213.50 (m).


1-Benzothiophen-4-ol

5 a) 5-Bromo-6,7-dihydro-1-benothiophen-4(5H)-one



Ref: J. Chem. Res. (S) 1993, 192-193. Bromine (6.4 g, 40 mmol) in dry carbon tetrachloride containing a few drops of diethyl ether (20 mL) was added dropwise to a well stirred solution 6,7-dihydro-1-benothiophen-4(5H)-one (6.08 g; 40 mmol) in dry
10 diethyl ether (250 mL) allowing the solution to decolourise between additions and the temperature maintained at -10°C. Once the addition was complete, the solution was allowed to warm slowly to room temperature. Water (200 mL) was slowly added and the mixture transferred to a separating funnel with ether (100 mL). The organic phase was washed with water (100 mL), dried over magnesium sulfate and evaporated to an oil
15 which solidified on standing (8.56 g, 88%), this material was used without further purification. δ_{H} (300 MHz, CD₃OD) 7.36 (1H, d, Ar) 7.30 (1H, d, Ar), 4.63 (1H, t, CH) 3.20 (2H, m, CH₂), 2.56 (2H, m, CH₂).

b) 1-Benzothiophen-4-ol




20 5-Bromo-6,7-dihydro-1-benothiophen-4(5H)-one (11.4 g, 50 mmol), lithium bromide (10g) and lithium carbonate (7.4 g) were refluxed for 3 h in dry *N,N*-dimethylformamide (250 mL) under nitrogen. The solvent was evaporated *in vacuo* and the residue treated with cold aqueous hydrochloric acid (1 N, 250 mL). Extracted into diethyl ether (3 x 200
25 mL). The ethereal layer was extracted with 10% aqueous sodium hydroxide solution (2x). Combined aqueous layers were acidified and extracted into ether. Dried over magnesium sulfate and evaporated to an oil. Purified by chromatography eluting silica gel with ethyl acetate – hexane (4-6%). Combined fractions were evaporated to a light yellow oil which

-51-

crystallised on standing, this material was triturated with cyclohexane to give white plates (3.6 g; 51%). δ_H (300 MHz, CD_3OD) 7.45 (1H, d, Ar), 7.30-7.40 (2H, m, Ar), 7.12 (1H, m, Ar), 6.70 (1H, m, Ar).

5 **5-Fluoro-benzo[b]thiophen-4-ol**

a) 5-Fluoro-6,7-dihydro-5H-benzo[b]thiophen-4-one




10

Add trimethylsilyl trifluoromethanesulfonate (18.5 mL, 102 mmol, 1.3 equiv.) over 5 minutes to a cold (0°C) stirred solution of solution 6,7-dihydro-1-benothiophen-4(5H)-one (12.04 g, 79.1 mmol, 1 equiv.) and triethylamine (33 mL, 237 mmol, 3 equiv.) in dry dichloromethane (200 mL). Stir the reaction mixture at 0°C for 5 minutes and then warm to room temperature for 1h10min before adding water. Separate the layers, extract the aqueous layer twice with dichloromethane, dry the combined organic extracts over anhydrous magnesium sulfate, filter, and concentrate under reduced pressure. Dissolve the resulting crude silylenol ether in anhydrous dimethylformamide (200 mL), place the reaction mixture in a room temperature water bath, and add 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate) (SelectfluorTM) (31.06 g, 87.7 mmol, 1.1 equiv.) in one portion. Stir the reaction mixture at room temperature for 15 minutes then add tetrabutylammonium fluoride (1M in THF, 87 mL, 87 mmol, 1.1 equiv.) and stir at room temperature for 1 hr before adding water and ethyl acetate. Separate the layers, extract the aqueous layer three times with ethyl acetate, wash the combined organic extracts successively with water (2 times) then 0.1N HCl (2 times), dry the combined organic extracts over anhydrous magnesium sulfate, filter, and concentrate under reduced pressure. Purify the resultant crude material by medium pressure liquid chromatography eluting with 0 to 20% ethyl acetate in hexanes to afford the title compound as an orange solid (9.725 g, 72%). δ_H (400 MHz, $CDCl_3$) 2.41-2.54 (m, 1H), 2.56-2.67 (m, 1H), 3.10-

-52-


3.20 (m, 1H), 3.23-3.33 (m, 1H), 5.12 (ddd, 1H, $J = 47, 11, 4$ Hz), 7.15 (d, 1H, $J = 6$ Hz), 7.41 (d, 1H, $J = 6$ Hz).

b) 5-Bromo-5-fluoro-6,7-dihydro-5H-benzo[b]thiophen-4-one



Add a solution of bromine (10.08 g, 63.1 mmol, 1.1 equiv.) in dry carbon tetrachloride (60 mL) dropwise via addition funnel over 1h20min to a cold (0°C) solution of 5-fluoro-6,7-dihydro-5H-benzo[b]thiophen-4-one (9.72 g, 57.1 mmol, 1 equiv.) in dry diethyl ether (300 mL). Once all the bromine is added warm to room temperature for 2 hours and add more bromine (0.7 M in CCl₄, 7 mL, 4.9 mmol, 0.09 equiv.) and stir the reaction mixture at room temperature for 1 hr before adding saturated aqueous sodium thiosulfate. The layers are separated and the aqueous layer is extracted with diethyl ether (three times). The combined organic extracts are dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. Purify the resultant crude material by medium pressure liquid chromatography eluting with 0 to 20% ethyl acetate in hexanes to afford the title compound (6.976 g, 49%). δ_H (400 MHz, CDCl₃) 2.67-2.78 (m, 1H), 2.93 (dddd, 1H, $J = 14, 4, 4, 4$ Hz), 3.24-3.31 (m, 2H), 7.21 (d, 1H, $J = 6$ Hz), 7.45 (d, 1H, $J = 6$ Hz).

c) 5-fluoro-benzo[b]thiophen-4-ol




Heat a mixture of 5-bromo-5-fluoro-6,7-dihydro-5H-benzo[b]thiophen-4-one (6.97 g, 28.0 mmol, 1 equiv.), lithium carbonate (4.34 g, 58.7 mmol, 2.1 equiv.), and lithium bromide (5.61 g, 64.6 mmol, 2.3 equiv.) in dry dimethylformamide (150 mL) at 150°C (internal temperature) for 2 hours. Cool the reaction mixture to room temperature, add ice

-53-

water, and then carefully add 5N HCl until gas evolution ceases and the mixture is acidic. Add ethyl acetate, separate the layers, and extract the aqueous layer with ethyl acetate (3 times). Extract the combined organic extracts with 2N sodium hydroxide (2 times), reacidify the aqueous layers with hydrochloric acid, and then re-extract the aqueous layer
5 with dichloromethane (3 times). Dry the dichloromethane extracts over anhydrous magnesium sulfate, filter, and concentrate under reduced pressure. Purify the resultant crude material by medium pressure liquid chromatography eluting with 0 to 10% ethyl acetate in hexanes to afford the title compound as a colorless solid (3.738 g, 79%). δ_H (400 MHz, $CDCl_3$) 5.35 (br s, 1H), 7.13 (dd, 1H, $J = 10, 8$ Hz), 7.34 (ddd, 1H, $J = 8, 4, 1$
10 Hz), 7.42 (d, 1H, $J = 6$ Hz), 7.49 (dd, 1H, $J = 6, 1$ Hz).

Boron Tribromide Demethylation: General procedure

1-Benzothiophen-7-ol



15

A solution of boron tribromide (115 μ l, 1.21 mmol) was added dropwise at room temperature to a stirred solution of 1-benzothiophen-7-ol (200 mg, 1.21 mmol) in dry dichloromethane (10 mL). The resulting solution was allowed to stir at room temperature for a further 1 hr, after which the solvent was removed *in vacuo* and the residue taken up
20 in ethyl acetate (20 mL) and extracted with aqueous hydrochloric acid (2 N, 10 mL). The organic phase was dried ($MgSO_4$) and the solvent was removed *in vacuo*. The resulting dark yellow oil was purified by flash chromatography eluting silica gel with hexane:ethyl acetate [4:1] to yield a white solid (68 mg, 38%); δ_H (300 MHz, $CDCl_3$) 7.50-7.39 (2H, m, Ar), 7.29-7.21 (1H, m, Ar), 7.21-7.15 (1H, m, Ar), 6.70 (1H, d, Ar), 5.15 (1H, bs,
25 OH).

Similarly prepared were

5-Fluoro-1-benzothiophen-7-ol as a brown crystalline solid (393 mg, 42%); δ_H (300 MHz, $CDCl_3$) 7.50 (1H, d, Ar), 7.28 (1H, d, Ar), 7.10 (1H, dd, Ar), 6.58 (1H, dd, Ar), 5.40 (1H, s, OH).

- 5 **4-Trifluoromethyl-1-benzothiophen-6-ol** as a brown crystalline solid (1.576 g, 62%); δ_H (300 MHz, $CDCl_3$) 7.50-7.40 (3H, m, Ar), 7.22 (1H, d, Ar), 5.30 (1H, bs, OH).

5-Fluoro-1-benzothiophen-4-ol as a white crystalline solid (0.074 g, 21%); δ_H (300 MHz, $CDCl_3$) 7.50 (1H, d, Ar), 7.42 (1H, d, Ar), 7.35 (1H, m, Ar), 7.10 (1H, t, Ar), 5.40
10 (1H, bs, OH).

4-Methyl-1-benzothiophen-7-ol as an oil (290 mg, 79%); δ_H (300 MHz, $CDCl_3$) 7.44 (1H, d, Ar), 7.32 (1H, d, Ar), 7.00 (1H, d, Ar), 6.61 (1H, d, Ar), 4.92 (1H, s, OH), 2.52 (3H, s, CH_3).

15 **7-Fluoro-1-benzothiophen-4-ol** as a solid (0.68 g, 79%); δ_H 7.45 (1H, m, ArH), 7.40 (1H, d, ArH), 6.90 (1H, t, ArH) and 6.74 (1H, m, ArH) and 5.00 (1H, br. s, OH).

3-Chloro-4-fluoro-1-benzothiophen-7-ol as a white solid (145 mg, 97%); δ_H (300 MHz, $CDCl_3$) 7.25 (1H, s, Ar), 7.05-6.85 (1H, m, Ar), 6.72-6.61 (1H, dd, Ar).

3-Methyl-4-fluoro-1-benzothiophen-7-ol as a white solid (447 mg, 69%); δ_H (300 MHz, $CDCl_3$) 7.28 (1H, s, Ar), 6.99 (1H, s, OH), 6.90-6.78 (1H, m, Ar), 6.60 (1H, dd, Ar), 2.57 (3H, s, CH_3).

25 **7-Fluoro-3-methyl-1-benzothiophen-4-ol** as a solid (0.77 g, 70%); δ_H (300 MHz, $CDCl_3$) 7.26 (1H, s, ArH), 6.85-6.77 (1H, m, ArH), 6.58-6.50 (1H, m, ArH), 4.98 (1H, s, OH) and 2.65 (3H, s, CH_3).

30 **2-Fluoro-1-benzothiophen-7-ol** as a colourless oil (502 mg, 50%); δ_H (300 MHz, $CDCl_3$) 7.35-7.12 (3H, m, Ar), 6.72-6.63 (1H, dd, Ar).

-55-

2-Fluoro-1-benzothiophen-4-ol as a colourless oil (213 mg, 55%); δ_H (300 MHz, $CDCl_3$) 7.44 (1H, d, Ar), 7.41-7.12 (2H, m, Ar), 6.72-6.63 (1H, dd, Ar).

5 **7-Hydroxy-1-benzothiophene-2-carbonitrile** as a solid (3.9 g, 74%). δ_H (250 MHz, DMSO- D_6) 6.98 (dd, $J=7.87$, 0.94 Hz, 1 H) 7.37 (t, $J=7.87$ Hz, 1 H) 7.49 (dd, $J=7.87$, 0.94 Hz, 1 H) 8.34 (s, 1 H) 10.87 (s, 1 H). Negative FIA: $M-1 = 174.1$.

10 **4-Hydroxy-1-benzothiophene-2-carbonitrile** as a solid (0.65 g, 95%) δ_H (300 MHz, $CDCl_3$) 8.05 (1H, s, 3-ArH), 7.43-7.34 (2H, m, ArH), 7.80-7.75 (1H, m, ArH) and 5.68 (1H, br. s, OH). Negative FIA: $M-1 = 174.1$.


15 **4-Fluoro-7-hydroxy-1-benzothiophene-2-carbonitrile** as a solid (160 mg, 27%); δ_H (300 MHz, $CDCl_3$) 7.94 (1H, s, 3-ArH), 7.04-6.92 (1H, m, ArH), 6.85-6.76 (1H, m, ArH) and 5.52 (1H, br. s, OH).

20 **6-Hydroxy-1-benzothiophene-2-carbonitrile** as a solid ; (0.36 g, 64%); δ_H (300 MHz, D_4 -Methanol) 7.85 (1H, s, ArH), 7.73-7.62 (1H, m, ArH), 7.16 (1H, s, ArH) and 6.95-6.83 (1H, m, ArH): $M+1 = 176.1$.

1-Benzofuran-7-ol, synthesised from 7-methoxy-1-benzofuran, (Ref: Musser, J.H.; Chakraborty, U; Bailey, K; Sciortino, S; Whyzmuzis, C; Amin, D; Sutherland, C.A. J. Med. Chem. (1987), 30(1), 62-7.) as a solid (0.73 g, 82%); δ_H (300 MHz, $CDCl_3$) 7.61 (1H, d, Ar), 7.16 (2H, m, Ar), 6.82 (2H, m, Ar), 5.37 (1H, bs, -OH).

25

6-Fluoro-1-benzothiophene-7-ol




-56-

(Ref: Briner, K; Burkholder, T.P; Conway, R.G; Cunningham, B.E; Finley, D.R; Heinz, L.J; Jesudason, C.D; Kohlman, D.T; Liang, S.X; Xu, Y.C. Preparation and use of serotonergic benzothiophenes. WO 0109126 A1. Chem. Abs. 134:162912).

To a solution of 7-bromo-6-fluoro-1-benzothiophene (0.2 g, 0.9 mmol) and trimethylborate (0.2 mL, 1.8 mmol) at -78°C was added *tert*-butyllithium dropwise. After 10 mins at -78°C the reaction was quenched by pouring onto saturated ammonium chloride. This was extracted with ethyl acetate (3 x 10 mL) and the solvent removed *in vacuo* from the combined organic extracts. The residue was taken up in ethyl acetate (4 mL) and 10% aqueous hydrochloric acid (4 mL) was added, the mixture was stirred at room temperature for 1 h. The organic layer was separated and the aqueous layer extracted with ethyl acetate (2 x 10 mL). The combined organic extracts were dried (MgSO₄) and the solvent removed *in vacuo*. The residue was taken up in THF (10 mL), water (2 mL) and cooled to 0°C then 10% aqueous sodium hydroxide (2 mL) and 28% hydrogen peroxide (1 mL) were added to this and stirred for 0.5 h at 0°C. The mixture was warmed to room temperature and stirred for 2 hours, before a acetic acid (3 mL) was added. The mixture was extracted with ethyl acetate (3 x 10 mL), dried (MgSO₄) and the solvent removed *in vacuo*, to give a purple solid. This was purified by flash chromatography with a gradient of 0-20% ethyl acetate in *iso*-hexane to give the title compound (56 mg, 38%); δ_H (300 MHz, CDCl₃) 7.41 (4H, m, ArH).

4-Cyano-7-hydroxy benzo[b]thiophene




To a solution of 4-cyano-7-methoxy benzo[b]thiophene (450 mg, 2.38 mmol, 1 equiv.) in dry DMF (20 mL) was added sodium ethanethiolate (80% technical grade, 1.34 g, ~13 mmol, ~5 equiv.) and the reaction mixture was heated at 150°C for 2 hr. The mixture was cooled to room temperature and ethyl acetate and 1N HCl were added and the layers were separated. The aqueous layer was extracted with ethyl acetate and the combined organic extracts were washed with brine (3 times), dried over anhydrous magnesium sulfate,

- 57 -

filtered, and concentrated under reduced pressure. The acquired material thus obtained was purified via medium pressure liquid chromatography eluting with 30% ethyl acetate/70% hexanes to afford the title compound (414 mg, 99%) as a colorless solid; δ_{H} (400 MHz, CD_3OD) 6.80 (1H, d, $J = 8$ Hz), 7.47 (1H, d, $J = 6$ Hz), 7.64 (1H, d, $J = 8$ Hz), 7.83 (1H, d, $J = 6$ Hz).


1-Methyl-1H-indol-5-ol



(Ref: Taborsky, R.G.; Delvigs, P; Palaic, D; Bumpus, F.M. J. Med. Chem. (1967), 10(3), 403-7). To a solution of 5-benzyloxy-1-methyl-1H-indole (2 g, 8.9 mmol) in ethanol (20 mL) was added potassium hydroxide (0.62 g, 11.2 mmol). The resulting solution was allowed to stir at room temperature for 10 mins before evaporating the ethanol *in vacuo*. The residue was taken up in acetone (75 mL) and sodium sulfate (6.4 g, 44.8 mmol) was added, followed by dimethyl sulfate (0.87 mL, 8.9 mmol) *via* syringe. The solution was stirred for 0.5 h, then filtered and evaporated *in vacuo*. The resulting residue was then taken up in ethanol (50 mL) and 10% palladium on charcoal (0.4 g) was added. This solution was stirred under a hydrogen atmosphere for 4 h, then filtered through celite and the solvent evaporated *in vacuo*. This material was purified by flash chromatography, eluting silica gel with hexane:ethyl acetate (100:0 to 50:50) to give the product. (0.48 g, 37%); δ_{H} (300 MHz, CDCl_3) 7.15 (1H, d, Ar), 7.01 (2H, m, Ar), 6.8 (1H, m, Ar), 6.32 (1H, m, Ar), 3.73 (3H, s, NCH_3).


1-Methyl-1H-indol-7-ol

a) 7-Benzyloxy-1-methyl-1H-indole




-58-

To a solution of 7-benzyloxy-1*H*-indole (Ref: Dobson, D; Todd, A; Gilmore, J. Synth. Commun. (1991), 21(5), 611-17) (1.29 g, 5.78 mmol) in ethanol (30 mL) was added potassium hydroxide (0.41 g, 7.23 mmol) and dichloromethane (5 mL) of to help solubilize the starting material. The resulting solution was allowed to stir at room temperature for 10 min before evaporating the solvent *in vacuo*. The residue was taken up in acetone (75 mL) and sodium sulfate (4.9 g, 34.7 mmol) was added followed by dimethyl sulfate *via* syringe (0.62 mL, 6.3 mmol). The solution was stirred for 1 h, then filtered and evaporated *in vacuo*. This material was purified by flash chromatography, eluting silica gel with hexane: ethyl acetate (100:0 to 10:1) to give the product. (1.12 g, 82%); Mass spectrum (ion spray): $m/z = 238.1$ ($M+1$).

b) 1-Methyl-1*H*-indol-7-ol


To a solution of 7-benzyloxy-1methyl-1*H*-indole in 20 mL of ethanol was added 10% palladium on charcoal (0.2 g). This solution was stirred under balloon pressure hydrogen atmosphere for 4 h, then filtered through celite and concentrated *in vacuo*. This material was purified by flash chromatography, eluting silica gel with hexane:ethyl acetate (100:0 to 50:50) to give the product (0.58 g, 87%); Mass spectrum (TOF): $m/z = 147.1$ (M).

20 Isoquinolin-4-ol

The title compound was prepared as described in *Tetrahedron*, **1963**, *19*, 827-832.

Isoquinolin-6-ol


25 a) 6-Methoxy-isoquinoline



-59-


The title compound was prepared as described in *Synth. Commun.*, **1999**, 29, 1617-1625.

b) Isoquinolin-6-ol




- 5 Heat a mixture of 6-methoxy-isoquinoline (2.1 g, 13.2 mmol) and pyridine hydrochloride (30 g) in a heavy walled screw cap sealed tube at 160°C overnight. Cool to room temperature, add water and concentrated ammonium hydroxide to bring the pH of the mixture to 10-11, extract with ethyl acetate (4 times), wash the combined organic extracts with water (4 times), and concentrate under reduced pressure. Purification by medium
- 10 pressure liquid chromatography eluting with 0-3% of 2N NH₃/MeOH in dichloromethane afford the title compound (520 mg, 27%): δ_H (DMSO-d₆, 400 MHz): 7.09 (s, 1H), 7.19 (dd, 1H, $J = 9, 2$ Hz), 7.56 (d, 1H, $J = 6$ Hz), 7.94 (d, 1H, $J = 9$ Hz), 8.29 (d, 1H, $J = 6$ Hz), 9.05 (s, 1H), 10.36 (s, 1H).

15 **[1,7]Naphthyridin-5-ol**




The title compound was prepared as described in *Liebigs Annalen Der Chemie*, **1979**, 443-445.

20 **5-Hydroxyisoquinoline**



The title compound is commercially available and was purchased from the Aldrich Chemical Company.

-60-


5-Quinolinol

The title compound is commercially available and was purchased from the Aldrich Chemical Company.

5

Benzo[d]isothiazol-4-ol

a) 4-Methoxy-benzo[d]isothiazole




To a solution of 2-fluoro-6-methoxybenzaldehyde (2.0 g, 13.0 mmol) in 2-methoxyethanol (10 mL) in a sealed tube was added sulfur (416 mg, 13.0 mmol) and aqueous ammonium hydroxide (10 mL). The solution was heated to 160 degC for 18 h and was then cooled to rt. The reaction was partitioned between dichloromethane and water. The organic layer was separated and the aqueous layer was extracted with 2 x 50 mL dichloromethane. The combined organic phases were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with EtOAc:hexane [0:100 to 4:6] to yield the title compound as an oil (1.51 g, 70%); Mass spectrum (ion spray): m/z = 165.9 (m+1).

10

15

b) Benzo[d]isothiazol-4-ol



20

To a sealed tube was added 4-methoxy-benzo[d]isothiazole (760 mg, 4.60 mmol) and pyridine hydrochloride (5.5 g, 48 mmol). The reaction was heated to 150 °C for 18 h and was then cooled to rt. The mixture was partitioned between dichloromethane and water. The organic phase was separated and the aqueous layer was extracted with 2 x 30 mL


-61-

dichloromethane. The combined organic phases were dried (MgSO_4) and concentrated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with EtOAc:hexane [0:100 to 3:7] to yield the title compound as a solid (223 mg, 32%); Mass spectrum (ion spray): $m/z = 151.9$ ($m+1$).

5

7-methyl-benzo[d]isothiazol-4-ol


a) 7-Bromo-4-methoxy-benzo[d]isothiazole



To a solution of 4-methoxy-benzo[d]isothiazole (prepared as described above) (1.0 g, 6.05 mmol) in carbon tetrachloride (20 mL) at 0°C was added bromine (310 μL , 6.05 mmol) in carbon tetrachloride (10 mL). The reaction was allowed to stir at 0°C for 3 h and was then warmed to rt. Saturated aqueous NaHCO_3 and dichloromethane were added and the organic phase was separated. The aqueous phase was extracted with 2 x 20 mL dichloromethane. The combined organic phases were dried (MgSO_4) and concentrated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with EtOAc:hexane [0:100 to 1:20] to yield the title compound (980 mg, 66%): δ_{H} (300 MHz, CDCl_3): 9.09 (1H, s), 7.52 (1H, d, $J = 8.1$ Hz), 6.67 (1H, d, $J = 8.4$ Hz), 4.00 (3H, s).

15

b) 7-methyl-benzo[d]isothiazol-4-ol



20


A solution of 7-bromo-4-methoxy-benzo[d]isothiazole (460 mg, 1.88 mmol), K_2CO_3 (780 mg, 5.64 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (217 mg, 0.188 mmol) in 1,4-dioxane (5 mL) was added trimethylboroxine (290 μL , 2.07 mmol) and the solution was heated to 110°C for 18 h. The reaction was cooled to rt and diluted with water and dichloromethane. The

- 62 -

organic phase was separated and the aqueous phase was extracted with 2 x 30 mL dichloromethane. The combined organic phases were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with EtOAc:hexane [0:100 to 1:10] to yield 4-methoxy-7-methyl-benzo[d]isothiazole (88 mg, 26%). A method similar to that described for the preparation of benzo[d]isothiazol-4-ol (above) using 4-methoxy-7-methyl-benzo[d]isothiazole (88 mg, 0.491 mmol) and pyridine hydrochloride (567 mg, 5 mol) gave the title compound (30 mg, 37%): δ_H (300 MHz, CDCl₃): 8.99 (1H, s), 7.15 (1H, d, $J = 7.5$ Hz), 6.70 (1H, d, $J = 7.5$ Hz), 2.45 (3H, s).

Benzo[d]isothiazol-7-ol


a) 2-Fluoro-3,N-dimethoxy-N-methyl-benzamide



To a solution of 2-fluoro-3-methoxy-benzoic acid (5.0 g, 29.4 mmol) and PyBOP (13.7 g, 29.4 mmol) in 7:1 CH₂Cl₂:THF was added triethylamine (4.10 mL, 29.4 mmol) over a 10 min period. *N,O*-Dimethylhydroxylamine hydrochloride (2.87 g, 29.4 mL) was then added and the reaction was allowed to stir at rt for 3 h. The reaction was then partitioned between dichloromethane and water. The organic phase was separated and the aqueous phase was extracted with 2 x 100 mL dichloromethane. The combined organic phases were dried (MgSO₄) and concentrated *in vacuo*. The residue was taken up in ethyl acetate and was washed successively with 1N HCl, saturated aqueous NaHCO₃, and brine. The organic phase was again dried (MgSO₄) and concentrated *in vacuo* to yield the title compound (2.30 g, 37%).


b) 2-Fluoro-3-methoxy-benzaldehyde

-63-




To a solution of 2-fluoro-3,*N*-dimethoxy-*N*-methyl-benzamide (2.30 g, 10.8 mmol) in THF (20 mL) at -78°C was added 1M DIBAL-H in toluene (12 mL, 12 mmol). The reaction stirred at -78°C for 3 h and then the remaining 1M DIBAL-H in toluene (4.2 mL, 4.2 mmol) was added to the reaction. The reaction was allowed to stir at -78°C for 30 min and was then warmed to rt. The reaction was quenched slowly with saturated aqueous NH_4Cl . The organic phase was separated and the aqueous phase was extracted with 2 x 50 mL ethyl acetate. The combined organic phases were washed successively with 1N HCl and brine. The organic phase was dried (MgSO_4) and concentrated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with EtOAc:hexane [0:100 to 1:1] to yield the title compound (1.41 g, 85%): δ_{H} (300 MHz, CDCl_3): 10.38 (1H, s), 7.43-7.40 (1H, m), 7.24-7.15 (2H, m), 3.95 (3H, s).

c) 7-methoxy-benzo[d]isothiazole



A method similar to 4-methoxy-benzo[d]isothiazole using 2-fluoro-3-methoxy-benzaldehyde (410 mg, 2.66 mmol), sulfur (85 mg, 2.66 mmol), NH_4OH (5 mL), and 2-methoxyethanol (5 mL) gave the title compound (60 mg, 14%); Mass spectrum (ion-spray): $m/z = 165.8$ ($m+1$).

d) Benzo[d]isothiazol-7-ol




- 64 -

A method similar to that used in the preparation of benzo[d]isothiazol-4-ol using 7-methoxy-benzo[d]isothiazole (60 mg, 0.363 mmol) and pyridine hydrochloride (500 mg, 4.33 mmol) gave the title compound (26 mg, 47%); Mass spectrum (ion-spray): $m/z = 151.9$ ($m+1$).

5

4-Hydroxy-benzothiazole


a) 4-Methoxy-benzothiazole



2-Amino-4-methoxy-benzothiazole (1.00 g, 5.54 mmol) was added to a stirred solution of polyphosphoric acid (85%, 40 ml) at 60 °C. The resulting mixture was stirred at 60 °C until all the benzothiazole had dissolved. The resulting solution was then cooled to -10 °C and a solution of sodium nitrite (2.3 g, 33.3 mmol) in water (5 ml) was added so as to keep the internal temperature below -4 °C. After complete addition the resulting solution was added to a solution of hypophosphoric acid (50%, 15 ml) at 0 °C. After the evolution of gas had ceased the mixture was diluted with water and basified with NaHCO₃ (sat). The aqueous solution was extracted with CHCl₃ (3 x 200 ml) with the combined organic extracts dried (MgSO₄) and the solvent removed *in vacuo*. The resulting solid was recrystallised from EtOH:H₂O to give an orange solid (300 mg).


The liquor was concentrated and purified by flash chromatography eluting silica gel with hexane:EtOAc [4:1] to hexane:EtOAc [1:1] to give a further 210mg of product. $R_f = 0.38$ in hexane:ether [1:1]; δ_H (300 MHz, CDCl₃) 8.91 (1H, s, CH), 7.53 (1H, d, Ar), 7.39 (1H, t, Ar), 6.93 (1H, d, Ar), 4.07 (3H, s, OCH₃).

b) 4-Hydroxy-benzothiazole




-65-

Boron tribromide (3.09ml, 1M solution in DCM, 3.09 mmol) was added dropwise at 0 °C to a stirred solution of 4-methoxy-benzothiazole (510 mg, 3.09 mmol) in dry DCM (30ml). The resulting solution was warmed to 40 °C and allowed to stir overnight. The resulting solution was concentrated *in vacuo* and diluted with water and HCl (2N). The aqueous phase was neutralised to pH ~7 with NaHCO₃ and the solution extracted with EtOAc (3 x 100 ml) and the combined organic extracts dried (MgSO₄) and the solvent removed *in vacuo*. The resulting oil was purified by flash chromatography eluting silica gel with hexane:EtOAc [4:1] to hexane:EtOAc [7:3] to give the title compound as a tan solid (730mg, 80%); δ_H (300 MHz, CDCl₃) 7.59 (1H, s, CH), 7.46 (1H, dd, Ar), 7.36 (1H, t, Ar), 7.02 (1H, dd, Ar).

Thieno[3,2-c]pyridin-7-ol


The title compound was prepared as described in Patent GB 2010249A.

Thieno[2,3-c]pyridin-4-ol

The title compound was prepared as described in Patent GB 2010249A.

4-Fluoro-2,3-dihydrobenzo[b]thiophen-7-ol


a) 5-(2-Fluoro-5-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one



- 66 -


To a suspension of 2-fluoro-5-methoxybenzaldehyde (5.00 g, 32.46 mmol) and rhodanine (4.31 g, 32.46 mmol) in dry toluene (1000 mL) was added ammonium acetate (50 mg) and acetic acid (2 mL). The resulting suspension was allowed to stir at 120°C for 12 h under Dean-Stark apparatus before being allowed to cool and filtered. Resultant solid was washed with hexane and allowed to dry *in vacuo* to give an orange crystalline solid (8.00 g, 91%); δ_H (300 MHz, $CDCl_3$) 7.50 (1H, s, CH=C); 7.31 (1H, t, Ar), 7.20-7.11 (1H, m, Ar), 6.95-6.89 (1H, m, Ar), 3.80 (3H, s, OCH_3).

b) (2Z)-3-(2-Fluoro-5-methoxyphenyl)-2-mercapto-2-propenoic acid



5-(2-Fluoro-5-methoxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one (8.00g, 9.7 mmol) was added in one portion to 25% w/v sodium hydroxide solution (40 mL). This was allowed stir at reflux for 1 h. After this time the reaction was allowed to cool to room temperature and poured onto water (50 mL). This was washed with dichloromethane (50 mL), and the aqueous layer acidified to pH 2 with aqueous hydrochloric acid (2 N, 50 mL) to give a white suspension. Product was extracted with ether (2 x 60 mL), dried ($MgSO_4$) and solvent removed *in vacuo* to give a white solid (6.71 g, 100%); δ_H (300 MHz, CD_3OD) 7.85 (1H, s, Ar), 7.46-7.35 (1H, m, Ar), 7.11 (1H, t, Ar), 7.01-6.75 (2H, m, CH=, and SH), 3.80 (3H, s, OCH_3).

c) 4-Fluoro-7-methoxy-1-benzothiophene-2-carboxylic acid




(2Z)-3-(2-Fluoro-5-methoxyphenyl)-2-mercapto-2-propenoic acid (1.00 g, 4.38 mmol) was added in one portion to a solution of iodine (1.66 g, 6.56 mmol) in dimethoxyethane (10 mL). This was heated in the microwave with 300W at 160°C for 10 mins. After this time the reaction was allowed to cool to room temperature and poured onto saturated

- 67 -


sodium metabisulphite (200 mL) and ether (400 mL). Ether layer was separated and product extracted with aqueous sodium hydroxide (2 N, 2 x 100 mL). This was then acidified to pH 2 with aqueous hydrochloric acid (2 N, 250 mL), and product extracted with ether (2 x 150 mL). The combined organic extracts were dried (MgSO₄) and concentrated *in vacuo* to give a white solid (580 mg, 30%); δ_H (300 MHz, CD₃OD) 8.00 (1H, s, Ar), 7.30-7.19 (1H, m, Ar), 7.10-7.00 (1H, m, Ar), 3.95 (3H, s, OCH₃).

d) 4-Fluoro-7-methoxy-1-benzothiophene



4-Fluoro-7-methoxy-1-benzothiophene-2-carboxylic acid (2.00 g, 8.84 mmol) was added in one portion to DBU (8 mL) and dimethyl acetamide (10 mL). This was heated in the microwave with 300W at 200°C for 1 h. The reaction mixture was allowed to cool and poured onto water (100 mL). Product was extracted with hexane (2 x 100 mL), washed with aqueous hydrochloric acid (2 N, 50 mL), aqueous sodium hydroxide (2 N, 50 mL), and the combined organic extracts were dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by flash chromatography eluting silica gel with hexane:ethyl acetate [96:4] to give an oil (1.12 g, 70%); δ_H (300 MHz, CDCl₃) 7.4 (2H, s, Ar), 6.9 (1H, t, Ar), 6.60 (1H, dd, Ar), 3.91 (3H, s, OCH₃).

e) 4-Fluoro-7-methoxy-2,3-dihydrobenzo[b]thiophene




To a solution of 4-fluoro-7-methoxy-1-benzothiophene (1.55 g, 8.5 mmol, 1 eq) in trifluoroacetic acid (40 ml) was added triethylsilane (3.40 ml, 21.25 mmol, 2.5 eq). The mixture was heated to 60°C for 48 hours, then cooled to room temperature and the solvent removed *in vacuo*. The crude product was purified by flash chromatography with a gradient of 40-60% chloroform in heptane to give 1.24 g, 80% recovered starting material

- 68 -


and 199 mg, 13% yield of the title compound as a colourless oil: δ_H (300 MHz, $CDCl_3$) 3.78-6.58 (2H, m, ArH), 3.82 (3H, s, CH_3) and 3.44-3.30 (4H, m, SCH_2CH_2).

f) 4-Fluoro-2,3-dihydrobenzo[b]thiophen-7-ol



A BBr_3 demethylation of 4-fluoro-7-methoxy-2,3-dihydrobenzo[b]thiophene similar to that described for 4-hydroxy benzothiazole affords the title compound as a brown solid 251 mg: δ_H (300 MHz, $CDCl_3$) 6.57-6.48 (2H, m, ArH), 4.67 (1H, br. s, OH) and 3.43-3.23 (4H, m, SCH_2CH_2).


3-(Benzyl-methyl-amino)-N-methoxy-N-methyl-propionamide



Add potassium carbonate (63.50 g, 459 mmol) to a stirred solution of *N*-benzylmethylamine (14.8 mL, 115 mmol), 3-bromo-*N*-methoxy-*N*-methyl-propionamide (22.47 g, 115 mmol, prepared according to Jacobi, P. A.; Blum, C. A.; DeSimone, R. W.; Udodong, U. E. *S. J. Am. Chem. Soc.* **1991**, *113*, 5384-5392), and anhydrous acetonitrile (460 mL). Heat the reaction to reflux under nitrogen for 3 hours. Cool the reaction to room temperature and filter the reaction through Celite®. Wash the Celite® with ethyl acetate and concentrate on a rotary evaporator to give the crude product. Purify the crude product by flash chromatography on silica gel eluting with 0.5% concentrated ammonium hydroxide/5% ethanol/chloroform to yield 22.31 g (82%) of 3-(benzyl-methyl-amino)-*N*-methoxy-*N*-methyl-propionamide: mass spectrum (ion spray) m/z = 237.1(M+1); 1H NMR ($CDCl_3$) δ 7.31-7.21 (m, 5H), 3.65 (s, 3H), 3.53 (s, 2H), 3.17 (s, 3H), 2.80-2.76 (m, 2H), 2.67-2.63 (m, 2H), 2.23 (s, 3H).

1-(Benzyl-methyl-amino)-heptan-3-one


- 69 -



Add butyllithium (12.3 ml (1.6 M solution in hexane), 19.6 mmol) to a stirred solution of 3-(benzyl-methyl-amino)-*N*-methoxy-*N*-methyl-propionamide and anhydrous tetrahydrofuran (70 ml) at -40°C under N_2 . Stir for 1 hr at -40°C . Quench the reaction with saturated ammonium chloride (25 ml), allow the reaction to reach room temperature and add saturated sodium bicarbonate. Extract with ethyl acetate, wash with brine and dry over sodium sulfate. Filter off and concentrate to give the crude product. Purify the compound by flash chromatography, eluting with 2% ethanol/0.2% ammonium hydroxide/chloroform to yield 2.41 g (81%) of 1-(benzyl-methyl-amino)-heptan-3-one:


mass spectrum (ion spray) $m/z = 234$ ($M+1$); ^1H NMR (CDCl_3) δ 7.31-7.24 (m, 5H), 3.5 (s, 2H), 2.74-2.7 (m, 2H), 2.64-2.60 (m, 2H), 2.41 (t, 2H), 2.19 (s, 3H), 1.59-1.51 (m, 2H), 1.35- 1.28 (m, 2H), 0.91 (t, 3H).

1-(Benzyl-methyl-amino)-hexan-3-one



Using a method similar to that for 1-(Benzyl-methyl-amino)-heptan-3-one, propylmagnesium chloride (2 M solution in diethyl ether) affords the title compound: mass spectrum (ion spray) $m/z = 220$ ($M+1$): ^1H NMR (CDCl_3) δ 7.35-7.24 (m, 5H), 3.51 (s, 2H), 2.74-2.69 (m, 2H), 2.66-2.61 (m, 2H), 2.39 (t, 2H), 2.20 (s, 3H), 1.67-1.57 (m, 2H), 0.92(t, 3H).

(4-Cyclohexyl-3-oxo-butyl)-methyl-carbamic acid *tert*-butyl ester




Add dropwise bromomethylcyclohexane (16.96 mL, 0.121 mol) to a stirred warm solution of magnesium (granulae, 3.02 g, 0.124 mol), a crystal of iodine and tetrahydrofuran (130 mL). Heat the mixture to reflux for one hour. Add the Grignard reagent (30 mL) to a

-70-

stirred mixture of [2-(methoxy-methyl-carbamoyl)-ethyl]-methyl-carbamic acid *tert*-butyl ester (3.0 g, 12.0 mmol, prepared according to Blaney, P.; Grigg, R.; Rankovic, Z.; Thornton-Pett, M.; Xu, J. *Tetrahedron* **2002**, 1719-1737) and tetrahydrofuran (120 mL) kept at 0 °C under N₂. Stir the mixture for one h at 0 °C and for 2 h at room temperature.

- 5 Add more of the Grignard reagent (40 mL) and stir for another hour at room temperature. Add saturated aqueous ammonium chloride and separated the layers. Extract the water layer with diethyl ether (x3). Dry the combined organic layers, filter and concentrate. Purify the crude residue by flash column chromatography, eluting with ethyl acetate/hexane (1:9) to yield 1.0 g of the title compound. ¹H NMR (CDCl₃) δ 3.46-3.40 (m, 2H), 2.85 (s, 3H), 2.68-2.60 (m, 2H), 2.29 (d, 2H), 1.87-1.60 (m, 6H), 1.46 (s, 9H), 1.33-1.07 (m, 3H), 0.99-0.86 (m, 2H).
- 10


1-(Benzyl-methyl-amino)-heptan-3-ol



- 15 Add sodium borohydride (1.29 g, 34.1 mmol) to a stirred solution of 1-(benzyl-methyl-amino)-heptan-3-one (2.41 g, 10 mmol) and methanol (45ml) at 0 °C under N₂. Stir the reaction for 1 hr at 0 °C. Quench the reaction with water at 0 °C and concentrate under reduced pressure. Dissolve the residue in ethyl acetate, wash with brine and dry over sodium sulfate. Filter off and concentrate to give the crude compound. Purify the
- 20 compound by flash chromatography, eluting with 5% ethanol/0.5% ammonium hydroxide/chloroform to yield 2.22 g (91%) of 1-(benzyl-methyl-amino)-heptan-3-ol: mass spectrum (ion spray) m/z = 236 (M+1); ¹H NMR (CDCl₃) δ 7.34-7.23 (m, 5H), 3.76-3.72 (m, 1H), 3.53 (dd, 2H), 2.80-2.73 (m, 1H), 2.59-2.53 (m, 1H), 2.21 (s, 3H), 1.68-1.62 (m, 1H), 1.57-1.29 (m, 7H), 0.91 (t, 3H).

25


1-(Benzyl-methyl-amino)-hexan-3-ol



-71-


Using a method similar to that for 1-(Benzyl-methyl-amino)-heptan-3-ol, 1-(benzyl-methyl-amino)-hexan-3-one affords the title compound: mass spectrum (ion spray) m/z = 222 ($M+1$); ^1H NMR (CDCl_3) δ 7.34-7.24 (m, 5H), 3.79-3.73 (m, 1H), 3.55 (dd, 2H), 2.81-2.74 (m, 1H), 2.59-2.55 (m, 1H), 2.22 (s, 3H), 1.72-1.62 (m, 1H), 1.56-1.31 (m, 5H), 0.93 (t, 3H).

(4-Cyclohexyl-3-hydroxy-butyl)-methyl-carbamic acid *tert*-butyl ester



Using a method similar to that for 1-(Benzyl-methyl-amino)-heptan-3-ol, (4-cyclohexyl-3-oxo-butyl)-methyl-carbamic acid *tert*-butyl ester affords the title compound: ^1H NMR (CDCl_3) δ 3.90-3.80 (m, 1H), 3.62-3.52 (m, 1H), 2.88-2.96 (m, 1H), 2.83 (s, 3H), 1.80-1.60 (m, 6H), 1.56-1.32 (m, 3H), 1.47 (s, 9H), 1.31-1.08 (m, 4H), 0.98-0.77 (m, 2H).

1-(Benzyl-methyl-amino)-5-methyl-hexan-3-ol




Add *N*-benzylmethylamine (1.50 mL, 11.6 mmol) to a stirred solution of 1,8-diazabicyclo[5.4.0]undec-7-ene (0.0175 mL, 0.117 mmol) and anhydrous tetrahydrofuran (10 mL). Cool the solution to -15°C under nitrogen. Add acrolein (0.78 mL, 11.7 mmol) slowly and stir for 30 minutes at -15°C . Cool the reaction to -78°C . Add isobutylmagnesium chloride (11.0 mL, 2.0 M solution in diethyl ether, 22.0 mmol) and stir for 1 hour at -78°C . Quench the reaction with water at -78°C and then pour the reaction into 100 mL of 1N sodium hydroxide/saturated sodium bicarbonate (1:1). Extract with ethyl acetate (3 X 100 mL), wash the ethyl acetate with brine (100 mL), and dry the ethyl acetate over sodium sulfate. Filter off the sodium sulfate and concentrate on a rotary evaporator to give the crude product. Purify the crude product by flash chromatography on silica gel eluting with 0.3% concentrated ammonium hydroxide/3% ethanol/chloroform to yield 1.0010 g (37%) of 1-(benzyl-methyl-amino)-5-methyl-hexan-3-ol: mass spectrum

-72-


(ion spray) $m/z = 236.2(M+1)$; 1H NMR ($CDCl_3$) δ 7.34-7.23 (m, 5H), 6.08 (br s, 1H), 3.86-3.80 (m, 1H), 3.62 (d, 1H), 3.43 (d, 1H), 2.79-2.73 (m, 1H), 2.58-2.53 (m, 1H), 2.21 (s, 3H), 1.83-1.40 (m, 4H), 1.16-1.09 (m, 1H), 0.91-0.89 (m, 6H).

5 **1-(Benzyl-methyl-amino)-4-methyl-pentan-3-ol**



Using a method similar to that for 1-(Benzyl-methyl-amino)-5-methyl-hexan-3-ol, isopropylmagnesium chloride affords the title compound: mass spectrum (ion spray) $m/z = 222.1(M+1)$; 1H NMR ($CDCl_3$) δ 7.34-7.23 (m, 5H), 6.21 (br s, 1H), 3.63 (d, 1H),
 10 3.51-3.47 (m, 1H), 3.42 (d, 1H), 2.81-2.74 (m, 1H), 2.59-2.54 (m, 1H), 2.19 (s, 3H), 1.72-1.47 (m, 3H), 0.95 (d, 3H), 0.89 (d, 3H).

[3-(Benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-benzyl-methyl-amine




15 Add 1,1'-(azodicarbonyl)dipiperidine (1.6901 g, 6.698 mmol) to a stirred solution of 1-(benzyl-methyl-amino)-5-methyl-hexan-3-ol (1.0463 g, 4.445 mmol), 4-hydroxybenzo-thiophene (1.0027 g, 6.676 mmol), tributylphosphine (1.70 mL, 6.82 mmol), and anhydrous toluene (15 mL). Heat the reaction to 70 °C under nitrogen for 18 hours. Cool
 the reaction to room temperature and dilute with dichloromethane. Filter off the solid
 20 material and concentrate the solvent off on a rotary evaporator to give the crude product. Purify the crude product by flash chromatography on silica gel eluting with 10% ethyl acetate /dichloromethane to yield 0.9674 g (59%) of [3-(benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-benzyl-methyl-amine: mass spectrum (ion spray) $m/z = 368.3(M+1)$; 1H NMR ($CDCl_3$) δ 7.46-7.41 (m, 2H), 7.29-7.21 (m, 7H), 6.83 (d, 1H), 4.66-4.60 (m, 1H),

-73-

3.47 (s, 2H), 2.54-2.51 (m, 2H), 2.19 (s, 3H), 2.02-1.71 (m, 4H), 1.49-1.42 (m, 1H), 0.95 (d, 3H), 0.89 (d, 3H).

[3-(Benzo[b]thiophen-4-yloxy)-4-methyl-pentyl]-benzyl-methyl-amine




5

Using a method similar to that for [3-(Benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-benzyl-methyl-amine, 1-(benzyl-methyl-amino)-4-methyl-pentan-3-ol affords the title compound: mass spectrum (ion spray) $m/z = 354.3(M+1)$; 1H NMR ($CDCl_3$) δ 7.49 (d, 1H), 7.43 (d, 1H), 7.31-7.19 (m, 7H), 6.85 (d, 1H), 4.48-4.44 (m, 1H), 3.51-3.43 (m, 2H), 2.61-2.48 (m, 2H), 2.19 (s, 3H), 2.11-1.85 (m, 3H), 1.03 (d, 3H), 0.99 (d, 3H).

10

[3-(Benzo[b]thiophen-4-yloxy)-heptyl]-benzyl-methyl-amine




Using a method similar to that for [3-(Benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-benzyl-methyl-amine, 1-(benzyl-methyl-amino)-heptan-3-ol affords the title compound: mass spectrum (ion spray) $m/z = 368 (M+1)$; 1H NMR ($CDCl_3$) δ 7.45-7.41 (m, 2H), 7.29-7.19 (m, 7H), 6.80 (d, 1H), 4.56-4.51 (m, 1H), 3.47 (s, 2H), 2.55 (t, 2H), 2.20 (s, 3H), 2.01-1.91 (m, 2H), 1.90-1.63 (m, 3H), 1.45-1.29 (m, 4H), 0.89 (t, 3H).

15

[3-(Benzo[b]thiophen-4-yloxy)-hexyl]-benzyl-methyl-amine


20

-74-




Using a method similar to that for [3-(Benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-benzyl-methyl-amine, 1-(benzyl-methyl-amino)-hexan-3-ol affords the title compound: mass spectrum (ion spray) $m/z = 354$ ($M+1$); ^1H NMR (CDCl_3) δ 7.45-7.41 (m, 2H),
 5 7.29-7.20 (m, 7H), 6.81 (d, 1H), 4.58-4.53 (m, 1H), 3.47 (s, 2H), 2.54 (t, 2H), 2.20 (s, 3H), 2.03-1.90 (m, 2H), 1.88-1.60 (m, 2H), 1.53-1.38 (m, 2H), 0.93 (t, 3H).

[3-(Benzo[b]thiophen-4-yloxy)-4-cyclohexyl-butyl]-methyl-carbamic acid *tert*-butyl ester



Using a method similar to that for [3-(Benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-benzyl-methyl-amine, (4-cyclohexyl-3-hydroxy-butyl)-methyl-carbamic acid *tert*-butyl ester affords the title compound: mass spectrum (ion spray) $m/z = 418$ ($M+1$); ^1H NMR (CDCl_3) δ 7.49-7.47 (d, 1H), 7.43-7.41 (d, 1H), 7.31-7.30 (d, 1H), 7.24 (t, 1H), 6.72 (d, 1H),
 15 4.59-4.52 (m, 1H), 3.34-3.27 (m, 2H), 2.80 (s, 3H), 1.98-0.92 (m, 24).

***R,R*-(3-Propyl-oxiranyl)-methanol**




Add trans-2-hexen-1-ol (12 mL, 102 mmol), (-)-diethyl tartrate (2.1 mL, 12.3 mmol), and $\text{Ti}(\text{O}^i\text{Pr})_4$ (3.0 mL, 10.2 mmol) to a cooled (-20°C) solution of activated, dried, crushed
 20 4\AA molecular sieves (50 g) in dichloromethane (700 mL). After 30 minutes, add a dry [JACS, 1987, 109, 5765] solution of *t*BuOOH in dichloromethane ($\sim 5\text{M}$ in dichloromethane, 57 mL, 285 mmol). Stir for 4 hours at -20°C and filter the solids. Add

-75-

- 700 mL of 15% L-tartartic acid to the filtrate and stir for 20 minutes. Separate the layers, extract the aqueous layer with dichloromethane, and concentrate the combined organic extracts *in vacuo*. Add 300 mL diethyl ether to residue and cool to 0°C. Add cool (0°C) 15% NaOH, stir for 15 minutes, separate, and extract aqueous layer with diethyl ether.
- 5 Wash the organic layer with aqueous saturated sodium chloride, dry over anhydrous MgSO₄, filter, and concentrate *in vacuo*. Purify on silica gel eluting with 0-50% EtOAc/hexanes to give (*R,R*)-(3-propyl-oxiranyl)-methanol (5.69 g, 48%). ¹H NMR (CDCl₃) δ 3.97-3.88 (m, 1H), 3.68-3.59 (m, 1H), 3.00-2.91 (m, 2H), 1.83-1.68 (m, 1H), 1.61-1.41 (m, 4H), 0.97 (t, 3H). A similarly carried out Sharpless asymmetric
- 10 epoxidation of trans-2-hexen-1-ol is described in *J. Org. Chem.* **1994**, *59*, 4461 and is reported to proceed in >95% ee by ¹H NMR analysis of the Mosher esters.


(2R,3S)-3-(3,5-Dichloro-phenoxy)-hexane-1,2-diol



15


- Add sodium hydroxide (1N, 9 mL) to a stirred solution of 3,5-dichlorophenol in THF (9 mL) followed by a solution of (*R,R*)-(3-propyl-oxiranyl)-methanol in THF (5 mL). Heat the reaction mixture at 75°C overnight, cool to room temperature, add water, brine and
- 20 dichloromethane, and separate the layers. The aqueous layer is extracted with dichloromethane, the combined organic extracts are washed successively with 1N sodium hydroxide and water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. Analysis of the crude reaction mixture by ¹H NMR reveals a ~2:1 mixture of the C-3:C-1 adducts. Purification of the crude residue on silica gel eluting
- 25 with 0-25 % EtOAc/hexanes gives the major title compound (332 mg, 26%). ¹H NMR (DMSO-d₆): 0.86 (dd, 3H, J = 4, 4 Hz), 1.21-1.48 (m, 2H), 1.52-1.72 (m, 2H), 3.28-3.45 (m, 2H), 3.60-3.67 (m, 2H), 4.37-4.44 (m, 1H), 4.69 (dd, 1H, J = 6, 6 Hz), 4.88 (d, 1H, J = 5 Hz), 7.01-7.10 (m, 3H).

-76-

(2R,3S)-3-(2,4-Dichloro-phenoxy)-hexane-1,2-diol

5 Using a method similar to that for described for the preparation of (2R,3S)-3-(3,5-dichloro-phenoxy)-hexane-1,2-diol, the title compound is obtained as a powder (317 mg, 33%). ¹H NMR (DMSO-d₆): 0.85 (dd, 3H, J = 7, 7 Hz), 1.23-1.50 (m, 2H), 1.56-1.77 (m, 2H), 3.35-3.50 (m, 2H), 3.63-3.70 (m, 2H), 4.38-4.44 (m, 1H), 4.65 (dd, 1H, J = 6, 6 Hz), 4.89 (d, 1H, J = 5 Hz), 7.20 (d, 1H, J = 9 Hz), 7.31 (dd, 1H, J = 9, 3 Hz), 7.51 (d, 1H, J = 3 Hz).

10

(2S,3S)-Toluene-4-sulfonic acid 3-(3,5-dichloro-phenoxy)-2-hydroxy-hexyl ester

15 Add *p*-toluenesulfonyl chloride (339 mg, 1.78 mmol, 1.5 equiv.) to a cold (0°C) stirred solution of (2R,3S)-3-(2,4-dichloro-phenoxy)-hexane-1,2-diol (332 mg, 1.19 mmol, 1 equiv.) and stir at 0°C for 6 hr before slowly warming to room temperature overnight. Add dichloromethane and 1 N hydrochloric acid, separate the layers, extract the aqueous layer with dichloromethane (three times), washed the combined organic extracts with 1N hydrochloric acid, dry over anhydrous magnesium sulfate, filter, and concentrate under reduced pressure. Purification of the crude residue on silica gel eluting with 0-15 % EtOAc/hexanes gives the title compound as a colorless oil (306 mg, 59%). ¹H NMR (CD₃OD): 0.86 (dd, 3H, J = 7, 7 Hz), 1.23-1.47 (m, 2H), 1.63-1.71 (m, 2H), 2.42 (s, 3H) 3.83-3.88 (m, 1H), 4.00 (dd, 1H, J = 10, 5 Hz), 4.15 (dd, 1H, J = 10, 4 Hz), 4.29-4.37 (m


20

25

-77-

1H), 6.79 (d, 1H, $J = 2$ Hz), 6.98 (dd, 1H, $J = 2$ Hz), 7.32 (d, 1H, $J = 8$ Hz), 7.67 (dd, 1H, $J = 8$ Hz).


(2S, 3S)-Toluene-4-sulfonic acid 3-(2,4-dichloro-phenoxy)-2-hydroxy-hexyl ester



Using a method similar to that for described for the preparation of (2S, 3S)-toluene-4-sulfonic acid 3-(3,5-dichloro-phenoxy)-2-hydroxy-hexyl ester, the title compound is obtained as a colorless viscous oil (266 mg, 55%). ^1H NMR (CDCl_3): 0.90 (dd, 3H, $J = 7$, 7 Hz), 1.30-1.52 (m, 2H), 1.57-1.80 (m, 2H), 2.44 (s, 3H) 3.99-4.06 (m, 1H), 4.17 (dd, 1H, $J = 10$, 6 Hz), 4.25-4.36 (m 2H), 6.87 (d, 1H, $J = 9$ Hz), 7.14 (d, 1H, $J = 9$ Hz), 7.27-7.39 (m, 2H), 7.73 (d, 1H, $J = 8$ Hz).

EXAMPLE 1


[3-(Benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-methyl-amine




Add 1-chloroethylchloroformate (0.58 mL, 5.38 mmol) to a stirred solution of [3-(benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-benzyl-methyl-amine (0.9619 g, 2.62 mmol) and 1,2-dichloroethane (25 mL). Heat the reaction to reflux under nitrogen for 1.5 hours. Add methanol (30 mL) and heat the reaction at reflux for 30 minutes. Cool the reaction to room temperature and make it basic using 2M ammonia in methanol. Concentrate on a rotary evaporator to give the crude product. Purify the crude product by flash chromatography on silica gel eluting with 0.5% concentrated ammonium hydroxide/5% ethanol/chloroform to yield 0.6303 g (87%) of [3-(benzo[b]thiophen-4-yloxy)-5-methyl-hexyl]-methyl-amine: mass spectrum (ion spray) $m/z = 278.2(\text{M}+1)$; HPLC (90/5/5 to

-78-

0/95/5 water/acetonitrile/5% formic acid in water) XTerra MS C₁₈ 2.1mm X 50mm X 3.5micron: Retention time: 2.52 minutes, Purity: >99.9%.

EXAMPLE 25 **[3-(Benzo[b]thiophen-4-yloxy)-4-methyl-pentyl]-methyl-amine**


Using a method similar to example 1, [3-(benzo[b]thiophen-4-yloxy)-4-methyl-pentyl]-benzyl-methyl-amine affords the title compound: mass spectrum (ion spray) m/z = 264.1(M+1); HPLC (90/5/5 to 0/95/5 water/acetonitrile/5% formic acid in water) XTerra
10 MS C₁₈ 2.1mm X 50mm X 3.5micron: Retention time: 2.32 minutes, Purity: >99.9%.

EXAMPLE 3**[3-(Benzo[b]thiophen-4-yloxy)-heptyl]-methyl-amine**

15 Using a method similar to example 1, [3-(benzo[b]thiophen-4-yloxy)-heptyl]-benzyl-methyl-amine affords the title compound: mass spectrum (ion spray): m/z = 278 (M+1); HPLC (90/5/5 to 0/95/5 water/acetonitrile/5% formic acid) XTerra MS C₁₈ 2.1mm x 3.5mm: Retention time 2.60 minutes, Purity 100%.

20 **EXAMPLE 4****[3-(Benzo[b]thiophen-4-yloxy)-hexyl]-methyl-amine**


- 79 -



- Using a method similar to example 1, [3-(benzo[b]thiophen-4-yloxy)-hexyl]-benzyl-methyl-amine affords the title compound: mass spectrum (ion spray) $m/z = 264$ ($M+1$); HPLC (90/5/5 to 0/95/5 water/acetonitrile/5% formic acid) Xterra MS C₁₈ 2.1mm X 50mm X 3.5micron: Retention time 2.31 minutes, Purity 100%.

EXAMPLE 5

[3-(Benzo[b]thiophen-4-yloxy)-4-cyclohexyl-butyl]-methyl-amine




- 10 Add trifluoroacetic acid (5.5 ml, 71 mmol) to a stirred solution of [3-(benzo[b]thiophen-4-yloxy)-4-cyclohexyl-butyl]-methyl-carbamic acid tert-butyl ester (1.49 g, 3.6 mmol) and dichloromethane (80 ml) at 0 °C under N₂. Stir for 5 minutes at 0 °C and allow the reaction to reach room temperature. Stir for 90 minutes, add sodium bicarbonate. Partition between sodium bicarbonate and dichloromethane, wash the combined dichloromethane
- 15 layers with brine, dry over sodium sulfate. Filter and concentrate to give the crude compound. Purify the compound by flash chromatography, eluting with 3% ethanol/0.3% ammonium hydroxide/chloroform to yield 0.511 g (45%) of the title compound: mass spectrum (ion spray) $m/z = 318$ ($M+1$); HPLC (90/5/5 to 0/95/5 water/acetonitrile/5% formic acid) Xterra MS C₁₈ 2.1mm X 50mm X 3.5micron: Retention time 3.08 minutes,
- 20 Purity 100%.

EXAMPLE 6

3-(Benzo[b]thiophen-4-yloxy)-4-cyclohexyl-N-methylbutan-1-amine hydrochloride

a)


-80-



Enantiomer 1

Separate the racemic mixture of [3-(benzo[b]thiophen-4-yloxy)-4-cyclohexyl-butyl]-methyl-amine into the two enantiomers by chiral chromatography on a 15 cm x 4.6 mm i.d Chiralpak AD-H(3673) using 95% heptane/ 5% ethanol and 0.2% diethylamine as the mobile phase at a rate of 1.0 ml/min. Add dropwise with stirring 1M hydrochloric acid in diethyl ether (0.52 ml, 0.52 mmol, 1 eq) to a solution of the free base of the first eluting enantiomer (166 mg, 0.52 mmol, 1 eq) in diethyl ether (20 ml). Cool to 0 °C for several hours, filter the solid off and dry under vacuum to give the compound as a white solid (128 mg, 69%). ¹H NMR (300MHz, CD₃OD) δ 7.43-7.32 (3H, m, ArH), 7.18 (1H, t, J = 8.0 Hz, ArH), 6.81 (1H, d, J = 7.5 Hz, ArH), 4.76-4.61 (1H, m, 4-CH), 3.17-2.98 (2H, m, 2-CH₂), 2.58 (3H, s, NHCH₃), 2.22-1.89 (2H, m, 3-CH₂), 1.82-0.74 (13H, m, 6 x CH₂ and CH). LCMS m/z 318.1 [M+H].

b)




Enantiomer 2

Prepare the hydrochloride salt of the free base of the second eluting enantiomer (143 mg, 0.45 mmol) as described above to give the compound as a white solid (98 mg, 61%). ¹H NMR (300MHz, CD₃OD) δ 7.54-7.44 (3H, m, ArH), 7.30 (1H, t, J = 8.0 Hz, ArH), 6.93 (1H, d, J = 8.1 Hz, ArH), 5.00-4.73 (1H, m, 4-CH), 3.31-3.07 (2H, m, 2-CH₂), 2.69 (3H, s, NHCH₃), 2.31-1.99 (2H, m, 3-CH₂), 1.90-0.87 (13H, m, 6 x CH₂ and CH). LCMS m/z 318.1 [M+H].

EXAMPLE 7**3-(Benzo[b]thiophen-4-yloxy)-N,4-dimethylpentan-1-amine hydrochloride**

a)


-81-



Enantiomer 1

Separate the racemic mixture of [3-(benzo[*b*]thiophen-4-yloxy)-4-methyl-pentyl]-methyl-amine into the two enantiomers by chiral chromatography on a Chiralcel-AD-H(15cm) using 95% ethanol/ 5% isopropanol and 0.2% diethylamine as the mobile phase at a rate of 0.5 ml/min. Using a method similar to example 6, prepare the hydrochloride salt of the free base of the first eluting enantiomer (176 mg, 0.63 mmol) to give a white solid (159 mg, 79%). ¹H NMR (300MHz, CD₃OD) δ 7.56-7.45 (3H, m, ArH), 7.29 (1H, t, J = 8.0 Hz, ArH), 6.93 (1H, d, J = 8.7 Hz, ArH), 4.59-4.49 (1H, m, 4-CH), 3.25-3.10 (2H, m, 2-CH₂), 2.69 (3H, s, NHCH₃), 2.24-2.06 (2H, m, 3-CH₂) and 1.12-0.98 (6H, m, 2 x CH₃). LCMS m/z 264.1 [M+H].

b)




Enantiomer 2

Prepare the hydrochloride salt of the free base of the second eluting enantiomer (104 mg, 0.39 mmol) as described above to give the compound as a white solid (70 mg, 59%). ¹H NMR (300MHz, CD₃OD) δ 7.54-7.45 (3H, m, ArH), 7.29 (1H, t, J = 7.9 Hz, ArH), 6.93 (1H, d, J = 7.9 Hz, ArH), 4.64-4.46 (1H, m, 4-CH), 3.25-3.09 (2H, m, 2-CH₂), 2.69 (3H, s, NHCH₃), 2.26-2.04 (2H, m, 3-CH₂) and 1.12-0.96 (6H, m, 2 x CH₃). LCMS m/z 264.1 [M+H].

EXAMPLE 8**3-(Benzo[*b*]thiophen-4-yloxy)-N-methylhexan-1-amine hydrochloride**

a)


- 82 -



Enantiomer 1

Separate the racemic mixture of [3-(benzo[*b*]thiophen-4-yloxy)-hexyl]-methyl-amine into the two enantiomers by chiral chromatography on a 15 cm x 4.6 mm i.d Chiralpak AD-H(3687) using 95% Heptane/ 5% isopropanol and 0.2% diethylamine as the mobile phase
 5 at a rate of 0.5 ml/min. Prepare the hydrochloride salt of the free base as described in example 6 to give the compound as a white solid (52 mg, 53%). ¹H NMR (300MHz, CD₃OD) δ 7.43-7.33 (3H, m, ArH), 7.18 (1H, t, J = 8.3 Hz, ArH), 6.81 (1H, d, J = 7.5 Hz, ArH), 4.67-4.51 (1H, m, 4-CH), 3.17-2.91 (2H, m, 2-CH₂), 2.59 (3H, s, NHCH₃), 2.17-1.95 (2H, m, 3-CH₂), 1.81-1.59 (2H, m, CH₂), 1.58-1.24 (2H, m, CH₂) and 0.93-0.75
 10 (3H, m, CH₃). LCMS m/z 264.1 [M+H].

b)



Enantiomer 2


Prepare the hydrochloride salt of the free base of the second eluting enantiomer (128 mg, 0.48 mmol) as described above to give a white solid (90 mg, 62%): ¹H NMR (300MHz, CD₃OD) δ 7.41-7.31 (3H, m, ArH), 7.18 (1H, t, J = 8.2 Hz, ArH), 6.81 (1H, d, J = 7.9 Hz, ArH), 4.65-4.49 (1H, m, 4-CH), 3.20-2.96 (2H, m, 2-CH₂), 2.59 (3H, s, NHCH₃), 2.15-1.97 (2H, m, 3-CH₂), 1.79-1.51 (2H, m, CH₂), 1.49-1.27 (2H, m, CH₂) and 0.91-0.77
 15 (3H, m, CH₃). LCMS m/z 264.1 [M+H].

20

EXAMPLE 9**3-(Benzo[*b*]thiophen-4-yloxy)-N-methylheptan-1-amine hydrochloride**

a)

-83-




Enantiomer 1

Separate the racemic mixture [3-(benzo[b]thiophen-4-yloxy)-heptyl]-methyl-amine into their two enantiomers by chiral chromatography on a Chiralcel OD(3641) using 95% Heptane/ 5% ethanol and 0.2% diethylamine as the mobile phase at a rate of 0.5 ml/min.

- 5 Add dropwise a solution of hydrochloric acid in diethyl ether (2M) to a solution of the free base of the first eluting enantiomer (100 mg, 0.36 mmol) in EtOH (5 mL). Stir the mixture at room temperature for 10 minutes and evaporate all volatiles *in vacuo*. Shake the resulting amorphous solid in diethyl ether until a crystalline solid is formed. Filter off the solid and dry under vacuum to give the compound as a brown solid (90 mg, 77 %). ¹H
- 10 NMR (300MHz, DMSO-*d*₆) δ 8.85 (2H, bs), 7.66-7.64 (1H, m), 7.56-7.53 (1H, m), 7.46-7.44 (1H, m), 7.32-7.27 (1H, m), 6.97-6.94 (1H, m), 4.67-4.64 (1H, m), 3.37 (3H, s), 3.03-3.00 (2H, m), 2.10-2.03 (2H, m), 1.68-1.59(2H, m), 1.39-1.31 (4H, m), 0.87-0.82 (3H, m). LCMS m/z 278 [M+H].

15 b)




Enantiomer 2

- Prepare the hydrochloride salt of the free base of the second eluting enantiomer (118 mg, 0.42 mmol) as described above to give a brown solid (40 mg, 34 %). ¹H NMR (300MHz, DMSO-*d*₆) δ 8.79 (2H, bs), 7.66-7.64 (1H, m), 7.56-7.53 (1H, m), 7.46-7.44b (1H, m),
- 20 7.32-7.27 (1H, m), 6.97-6.94 (1H, m), 4.67-4.63 (1H, m), 3.32 (3H, s), 3.03-3.01 (2H, m), 2.09-2.02 (2H, m), 1.68-1.59 (2H, m), 1.39-1.31 (4H, m) and 0.87-0.82 (3H, m). LCMS m/z 278 [M+H].


EXAMPLE 10

- 25 (2S,3S)-3-(3,5-Dichloro-phenoxy)-1-methylamino-hexan-2-ol hydrochloride

- 84 -



Add methyl amine (5 mL, 40%wt in water) to a solution of (2S, 3S)-toluene-4-sulfonic acid 3-(3,5-dichloro-phenoxy)-2-hydroxy-hexyl ester (306 mg, 0.706 mmol) in 1,4-dioxane (10 mL) in a heavy walled screw top sealed tube, seal the tube, and heat at 50°C overnight. The mixture is cooled and concentrated under reduced pressure. Purification by medium pressure liquid chromatography eluting with 0-10% of 2N NH₃/MeOH in dichloromethane is followed by HCl salt formation by dissolving in methanol (10 mL), adding solid ammonium chloride (32 mg, 0.598 mmol) and sonicating for 15 minutes. The mixture is concentrated under reduced pressure and the residue is dissolved in water, frozen at -78°C, and freeze dried to afford the title compound as a colorless solid (170 mg, 73%): δ_H (CD₃OD, 400 MHz): 0.94 (dd, 3H, J = 7, 7 Hz), 1.31-1.55 (m, 2H), 1.60-1.79 (m, 2H), 2.72 (s, 3H), 3.11 (dd, 1H, J = 13, 10 Hz), 3.22 (dd, 1H, J = 13, 3 Hz), 3.97-4.05 (m 1H), 4.37-4.45 (m, 1H), 7.00-7.04 (m, 3H). Exact Mass calcd. for C₁₃H₁₉O₂NCl₂ (M+ free base): 292.0871; found: 292.0879.

EXAMPLE 11**(2S,3S)- 3-(2,4-Dichloro-phenoxy)-1-methylamino-hexan-2-ol tartrate**

Add methyl amine (3 mL, 40%wt in water) to a solution of (2S, 3S)-toluene-4-sulfonic acid 3-(2,4-dichloro-phenoxy)-2-hydroxy-hexyl ester (266 mg, 0.614 mmol) in 1,4-dioxane (6 mL) in a heavy walled screw top sealed tube, seal the tube, and heat at 50°C overnight. The mixture is cooled and concentrated under reduced pressure. Purification

- 85 -

by medium pressure liquid chromatography eluting with 0-10% of 2N NH₃/MeOH in dichloromethane is followed by L-tartrate salt formation by dissolving in methanol, adding L-tartrate (65.6 mg, 0.437 mmol) and sonicating. The mixture is concentrated under reduced pressure and the residue is dissolved in water, frozen at -78°C, and freeze
5 dried to afford the title compound as a colorless solid (172.8 mg, 64%): δ_{H} (CD₃OD, 400 MHz): 0.94 (dd, 3H, $J = 8, 8$ Hz), 1.34-1.55 (m, 2H), 1.64-1.82 (m, 2H), 2.73 (s, 3H), 3.17 (dd, 1H, $J = 12, 10$ Hz), 3.33 (dd, 1H, $J = 12, 3$ Hz), 4.06-4.13 (m 1H), 4.40-4.48 (m, 3H), 7.17 17 (d, 1H, $J = 9$ Hz), 7.25 17 (dd, 1H, $J = 9, 3$ Hz), 7.40 17 (d, 1H, $J = 3$ Hz). Mass spectrum (ion spray): $m/z = 292$ (M⁺).

10 The compounds of the present invention may be used as medicaments in human or veterinary medicine. The compounds may be administered by various routes, for example, by oral or rectal routes, topically or parenterally, for example by injection, and are usually employed in the form of a pharmaceutical composition.

15 Such compositions may be prepared by methods well known in the pharmaceutical art and normally comprise at least one active compound in association with a pharmaceutically acceptable diluent or carrier. In making the compositions of the present invention, the active ingredient will usually be mixed with a carrier or diluted by a carrier, and/or
20 enclosed within a carrier which may, for example, be in the form of a capsule, sachet, paper or other container. Where the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Thus, the composition may be in the form of tablets, lozenges, sachets, cachets, elixirs, suspensions, solutions, syrups, aerosol (as a solid or in a liquid medium), ointments
25 containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, injection solutions and suspensions and sterile packaged powders.

30 Some examples of suitable carriers are lactose, dextrose, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as starch and petroleum jelly, sucrose sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl-

-86-

hydrobenzoate, talc, magnesium stearate and mineral oil. The compounds of formula (I) can also be lyophilized and the lyophilizates obtained used, for example, for the production of injection preparations. The preparations indicated can be sterilized and/or can contain auxiliaries such as lubricants, preservatives, stabilizers and/or wetting agents, emulsifiers, salts for affecting the osmotic pressure, buffer substances, colourants, flavourings and/or one or more further active compounds, e.g. one or more vitamins. Compositions of the invention may be formulated so as to provide, quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.

The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 500 mg, more usually about 25 to about 300 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary doses for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical carrier.

The pharmacological profile of the present compounds may be demonstrated as follows. All of the exemplified compounds above have been found to exhibit K_i values less than $1\mu\text{M}$ at the serotonin and norepinephrine transporters as determined using the scintillation proximity assays described below. Furthermore, all of the exemplified compounds above have been found to exhibit a K_i value less than 100nM at the serotonin transporter and/or a K_i value less than 100nM at the norepinephrine transporter as determined using the scintillation proximity assays described below. Preferred compounds of the present invention are those which exhibit a K_i value less than 100nM (preferably less than 50nM) at the serotonin transporter and a K_i value less than 100nM (preferably less than 50nM) at the norepinephrine transporter as determined using the scintillation proximity assays described below. Furthermore, all of the exemplified compounds above have been found to selectively inhibit the serotonin and norepinephrine transporters relative to the dopamine transporter. Preferred compounds of the present invention selectively inhibit the serotonin and norepinephrine transporters relative to the dopamine transporter by a factor of at least five using the scintillation proximity assays as described below.

- 87 -

Generation of stable cell-lines expressing the human dopamine, norepinephrine and serotonin transporters

Standard molecular cloning techniques were used to generate stable cell-lines expressing the human dopamine, norepinephrine and serotonin transporters. The polymerase chain reaction (PCR) was used in order to isolate and amplify each of the three full-length
5 cDNAs from an appropriate cDNA library. Primers for PCR were designed using the following published sequence data:

Human dopamine transporter: GenBank M95167. Reference: Vandenberg DJ, Persico
10 AM and Uhl GR. *A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs*. Molecular Brain Research (1992) volume 15, pages 161-166.

Human norepinephrine transporter: GenBank M65105. Reference: Pacholczyk T, Blakely,
15 RD and Amara SG. *Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter*. Nature (1991) volume 350, pages 350-354.

Human serotonin transporter: GenBank L05568. Reference: Ramamoorthy S, Bauman
AL, Moore KR, Han H, Yang-Feng T, Chang AS, Ganapathy V and Blakely RD.
20 *Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization*. Proceedings of the National Academy of Sciences of the USA (1993) volume 90, pages 2542-2546.

The PCR products were cloned into a mammalian expression vector (eg pcDNA3.1
25 (Invitrogen)) using standard ligation techniques. The constructs were then used to stably transfect HEK293 cells using a commercially available lipofection reagent (Lipofectamine™ – Invitrogen) following the manufacture's protocol.

Scintillation proximity assays for determining the affinity of test ligands at the
30 norepinephrine and serotonin transporters.

The compounds of the present invention are norepinephrine and serotonin reuptake inhibitors, and possess excellent activity in, for example, a scintillation proximity assay

-88-

(e.g. J. Gobel, D.L. Saussy and A. Goetz, J. Pharmacol. Toxicol. (1999), 42, 237-244). Thus ^3H -nisoxetine binding to norepinephrine re-uptake sites in a cell line transfected with DNA encoding human norepinephrine transporter binding protein and similarly ^3H -citalopram binding to serotonin re-uptake sites in a cell line transfected with DNA
5 encoding human serotonin transporter binding protein have been used to determine the affinity of ligands at the norepinephrine and serotonin transporters respectively.

Norepinephrine Binding Assay

Membrane Preparation:

10 Cell pastes from large scale production of HEK-293 cells expressing cloned human norepinephrine transporters were homogenized in 4 volumes 50mM Tris-HCl containing 300mM NaCl and 5mM KCl, pH 7.4. The homogenate was centrifuged twice (40,000g, 10min, 4°C) with pellet re-suspension in 4 volumes of Tris-HCl buffer containing the above reagents after the first spin and 8 volumes after the second spin. The suspended
15 homogenate was centrifuged (100g, 10min, 4°C) and the supernatant kept and re-centrifuged (40,000g, 20min, 4°C). The pellet was resuspended in Tris-HCl buffer containing the above reagents along with 10%w/v sucrose and 0.1mM phenylmethylsulfonyl fluoride (PMSF). The membrane preparation was stored in aliquots (1ml) at -80°C until required. The protein concentration of the membrane preparation
20 was determined using a bicinchoninic acid (BCA) protein assay reagent kit (available from Pierce).

[^3H]-Nisoxetine Binding Assay:

Each well of a 96 well microtitre plate was set up to contain the following:

25	50 μl	2nM [N-methyl- ^3H]-Nisoxetine hydrochloride (70-87Ci/mmol, from NEN Life Science Products)
	75 μl	Assay buffer (50mM Tris-HCl pH 7.4 containing 300mM NaCl and 5mM KCl)
	25 μl	Test compound, assay buffer (total binding) or 10 μM Desipramine HCl (non-specific binding)
30	50 μl	Wheatgerm agglutinin coated poly (vinyltoluene) (WGA PVT) SPA Beads (Amersham Biosciences RPNQ0001) (10mg/ml)
	50 μl	Membrane (0.2mg protein per ml)

- 89 -

The microtitre plates were incubated at room temperature for 10 hours prior to reading in a Trilux scintillation counter. The results were analysed using an automatic spline fitting programme (Multicalc, Packard, Milton Keynes, UK) to provide K_i values for each of the test compounds.

5

Serotonin Binding Assay

The ability of a test compound to compete with [^3H]-citalopram for its binding sites on cloned human serotonin transporter containing membranes has been used as a measure of test compound ability to block serotonin uptake via its specific transporter
10 (Ramamoorthy, S., Giovanetti, E., Qian, Y., Blakely, R., (1998) J. Biol. Chem. 273, 2458).

Membrane Preparation:

Membrane preparation is essentially similar to that for the norepinephrine transporter
15 containing membranes as described above. The membrane preparation was stored in aliquots (1ml) at -70°C until required. The protein concentration of the membrane preparation was determined using a BCA protein assay reagent kit.

[^3H]-Citalopram Binding Assay:

20 Each well of a 96 well microtitre plate was set up to contain the following:

50 μl 2nM [^3H]-Citalopram (60-86Ci/mmol, Amersham Biosciences)

75 μl Assay buffer (50mM Tris-HCl pH 7.4 containing 150mM NaCl and 5mM KCl)

25 μl Diluted compound, assay buffer (total binding) or 100 μM Fluoxetine (non-specific binding)

25 50 μl WGA PVT SPA Beads (40mg/ml)

50 μl Membrane preparation (0.4mg protein per ml)

The microtitre plates were incubated at room temperature for 10 hours prior to reading in a Trilux scintillation counter. The results were analysed using an automatic spline fitting programme (Multicalc, Packard, Milton Keynes, UK) to provide K_i (nM) values for each
30 of the test compounds.

Dopamine Binding Assay

-90-

The ability of a test compound to compete with [³H]-WIN35,428 for its binding sites on human cell membranes containing cloned human dopamine transporter has been used as a measure of the ability of such test compounds to block dopamine uptake via its specific transporter (Ramamoorthy et al 1998 *supra*).

5

Membrane Preparation:

Is essentially the same as for membranes containing cloned human serotonin transporter as described above.

10 [³H]-WIN35,428 Binding Assay:

Each well of a 96well microtitre plate was set up to contain the following:

50μl 4nM [³H]-WIN35,428 (84-87Ci/mmol, from NEN Life Science Products)

75μl Assay buffer (50mM Tris-HCl pH 7.4 containing 150mM NaCl and 5mM KCl)

25μl Diluted compound, assay buffer (total binding) or 100μM Nomifensine (non-specific binding)

15

50μl WGA PVT SPA Beads (10mg/ml)

50μl Membrane preparation (0.2mg protein per ml.)

The microtitre plates were incubated at room temperature for 120 minutes prior to reading in a Trilux scintillation counter. The results were analysed using an automatic spline fitting programme (Multicalc, Packard, Milton Keynes, UK) to provide K_i values for each of the test compounds.

20

Formalin Paw Assay

25 The analgesic effect of compounds of the invention for the treatment of persistent nociceptive pain was demonstrated using the well-known "formalin test." The formalin test is a model of persistent nociceptive activation induced by tissue injury which can lead to central sensitization. (Shibata, M., Ohkubo, T., Takahashi, H., and Inoki, R., "Modified formalin test: Characteristic biphasic pain response," *Pain* (1989) 38: 347-352; and Tjolsen, A., Berge, O.G., Hunskaar, S., Rosland, J.H., and Hole, K., "The formalin test: an evaluation of the method," *Pain* (1992) 51:5-17.) The effect of compounds of the invention on formalin-induced paw-licking behavior in the rat was investigated as an

30

-91-

index of persistent nociceptive activation. In this test, the injection of formalin under the skin on the dorsal lateral surface of the hind paw of rats causes an immediate and intense increase in the spontaneous activity of C fiber afferents. This activation evokes a distinctly quantifiable behavior indicative of pain, such as licking of the injected paw.

5 The behavioral response to formalin is biphasic, with an early phase that is short lived, followed by an extended tonic response or late phase of persistent nociceptive activation. Mechanisms causing the late phase response, such as central sensitization of pain transmitting neurons, are currently believed to contribute to various types of persistent pains.

10

Male Sprague-Dawley rats (200-250g; Charles River, Portage, MI) were maintained at constant temperature and light (12h light/12h dark) for 4-7 days prior to the studies. Animals had free access to food and water at all times prior to the day of the experiment.

15 Scoring in the formalin test was performed according to Coderre *et al.*, 1993b and Abbott *et al.*, 1995. (Coderre T.J., Fundytus M.E., McKenna J.E., Dalal S. and Melzack R. "The formalin test: a validation of the weighted-scores method of the behavioral pain rating," *Pain*(1993b) **54**: 43-50; and Abbott F.V., Franklin K.B.J. and Westbrook R.F. "The formalin test: scoring properties of the first and second phases of the pain response in rats," *Pain* (1995) **60**: 91-102.) The sum of time spent licking in seconds from time 0 to 20 5 minutes was considered the early phase while the late phase was taken as the sum of seconds spent licking from 15 to 40 minutes.

Data are presented as means with standard errors of means (\pm SEM). Data were evaluated 25 by one-way analysis of variance (ANOVA) and the appropriate contrasts analyzed by Tukey's test and Dunnett "t" test for two-sided comparisons.

The preferred compounds of the present invention show good stability to the action of the CYP 2D6 enzyme. This is advantageous because it is likely to lead to improved 30 metabolic stability of the compounds.

-92-

Stability to the CYP 2D6 enzyme may be determined according to the assay described below:

In Vitro Determination of the Interaction of compounds with CYP2D6 in Human Hepatic

5 Microsomes

Cytochrome P450 2D6 (CYP2D6) is a mammalian enzyme which is commonly associated with the metabolism of around 30% of pharmaceutical compounds. Moreover, this enzyme shows a genetic polymorphism with as a consequence a presence in the population of poor and normal metabolizers. A low involvement of CYP2D6 in the
10 metabolism of compounds (i.e. the compound being a poor substrate of CYP2D6) is desirable in order to reduce any variability from subject to subject in the pharmacokinetics of the compound. Also, compounds with a low inhibitor potential for CYP2D6 are desirable in order to avoid drug-drug interactions with co-administered drugs that are substrates of CYP2D6. Compounds may be tested both as substrates and as inhibitors of
15 this enzyme by means of the following assays.

CYP2D6 substrate assay

Principle:

This assay determines the extent of the CYP2D6 enzyme involvement in the total
20 oxidative metabolism of a compound in microsomes. Preferred compounds of the present invention exhibit less than 75% total metabolism via the CYP2D6 pathway.

For this in vitro assay, the extent of oxidative metabolism in human liver microsomes (HLM) is determined after a 30 minute incubation in the absence and presence of Quinidine, a specific chemical inhibitor of CYP2D6. The difference in the
25 extent of metabolism in absence and presence of the inhibitor indicates the involvement of CYP2D6 in the metabolism of the compound.

Materials and Methods:

Human liver microsomes (mixture of 20 different donors, mixed gender) were
30 acquired from Human Biologics (Scottsdale, AZ, USA). Quinidine and β -NADPH (β -Nicotinamide Adenine Dinucleotide Phosphate, reduced form, tetrasodium salt) were purchased from Sigma (St Louis, MO, USA). All the other reagents and solvents were of

-93-

analytical grade. A stock solution of the new chemical entity (NCE) was prepared in a mixture of Acetonitrile/Water to reach a final concentration of acetonitrile in the incubation below 0.5%.

The microsomal incubation mixture (total volume 0.1 mL) contained the NCE (4
5 μM), β -NADPH (1 mM), microsomal proteins (0.5 mg/mL), and Quinidine (0 or 2 μM) in 100 mM sodium phosphate buffer pH 7.4. The mixture was incubated for 30 minutes at 37 °C in a shaking waterbath. The reaction was terminated by the addition of acetonitrile (75 μL). The samples were vortexed and the denaturated proteins were removed by centrifugation. The amount of NCE in the supernatant was analyzed by liquid
10 chromatography /mass spectrometry (LC/MS) after addition of an internal standard. A sample was also taken at the start of the incubation (t=0), and analysed similarly.

Analysis of the NCE was performed by liquid chromatography /mass spectrometry. Ten μL of diluted samples (20 fold dilution in the mobile phase) were injected onto a Spherisorb CN Column, 5 μM and 2.1 mm x 100 mm (Waters corp.
15 Milford, MA, USA). The mobile phase consisting of a mixture of Solvent A/Solvent B, 30/70 (v/v) was pumped (Alliance 2795, Waters corp. Milford, MA, USA) through the column at a flow rate of 0.2 ml/minute. Solvent A and Solvent B were a mixture of ammonium formate $5 \cdot 10^{-3}$ M pH 4.5/ methanol in the proportions 95/5 (v/v) and 10/90 (v/v), for solvent A and solvent B, respectively. The NCE and the internal standard were
20 quantified by monitoring their molecular ion using a mass spectrometer ZMD or ZQ (Waters-Micromass corp, Machester, UK) operated in a positive electrospray ionisation.

The extent of CYP2D6 involvement (% of CYP2D6 involvement) was calculated comparing the extent of metabolism in absence and in presence of quinidine in the incubation.

25 The extent of metabolism without inhibitor (%) was calculated as follows:

$$\frac{(\text{NCE response in samples without inhibitor})_{\text{time 0}} - (\text{NCE response in samples without inhibitor})_{\text{time 30}}}{(\text{NCE response in samples without inhibitor})_{\text{time 0}}} \times 100$$

The extent of metabolism with inhibitor (%) was calculated as follows:

$$\frac{(\text{NCE response in samples without inhibitor})_{\text{time 0}} - (\text{NCE response in samples with inhibitor})_{\text{time 30}}}{(\text{NCE response in samples without inhibitor})_{\text{time 0}}} \times 100$$

where the NCE response is the area of the NCE divided by the area of the internal
30 standard in the LC/MS analysis chromatogram, time0 and time30 correspond to the 0 and 30 minutes incubation time.

- 94 -

The % of CYP2D6 involvement was calculated as follows:

$$\frac{(\% \text{ extent of metabolism without inhibitor}) - (\% \text{ extent of metabolism with inhibitor})}{\% \text{ extent of metabolism without inhibitor}} \times 100$$

CYP2D6 inhibitor assay

5 Principle:

The CYP2D6 inhibitor assay evaluates the potential for a compound to inhibit CYP2D6. This is performed by the measurement of the inhibition of the bufuralol 1'-hydroxylase activity by the compound compared to a control. The 1'-hydroxylation of bufuralol is a metabolic reaction specific to CYP2D6. Preferred compounds of the present invention exhibit an IC₅₀ higher than 6 μM for CYP2D6 activity, the IC₅₀ being the concentration of the compound that gives 50 % of inhibition of the CYP2D6 activity.

Material and methods:

Human liver microsomes (mixture of 20 different donors, mixed gender) were acquired from Human Biologics (Scottsdale, AZ). β-NADPH was purchased from Sigma (St Louis, MO). Bufuralol was purchased from Ultrafine (Manchester, UK). All the other reagents and solvents were of analytical grade.

Microsomal incubation mixture (total volume 0.1 mL) contained bufuralol 10 μM, β-NADPH (2 mM), microsomal proteins (0.5 mg/mL), and the new chemical entity (NCE) (0, 5, and 25 μM) in 100 mM sodium phosphate buffer pH 7.4. The mixture was incubated in a shaking waterbath at 37 °C for 5 minutes. The reaction was terminated by the addition of methanol (75 μL). The samples were vortexed and the denaturated proteins were removed by centrifugation. The supernatant was analyzed by liquid chromatography connected to a fluorescence detector. The formation of the 1'-hydroxybufuralol was monitored in control samples (0 μM NCE) and in the samples incubated in presence of the NCE. The stock solution of NCE was prepared in a mixture of Acetonitrile/Water to reach a final concentration of acetonitrile in the incubation below 1.0%.

The determination of 1'-hydroxybufuralol in the samples was performed by liquid chromatography with fluorimetric detection as described below. Twenty five μL samples were injected onto a Chromolith Performance RP-18e column (100 mm x 4.6 mm) (Merck KGaA, Darmstadt, Germany). The mobile phase, consisting of a mixture of

- 95 -

solvent A and solvent B whose the proportions changed according the following linear gradient, was pumped through the column at a flow rate of 1 ml/min:

Time (minutes)	Solvent A (%)	Solvent B (%)
0	65	35
2.0	65	35
2.5	0	100
5.5	0	100
6.0	65	35

5 Solvent A and Solvent B consisted of a mixture of 0.02 M potassium dihydrogenophosphate buffer pH3/ methanol in the proportion 90/10 (v/v) for solvent A and 10/90 (v/v) for solvent B. The run time was 7.5 minutes. Formation of 1'-hydroxybufuralol was monitored by fluorimetric detection with extinction at λ 252 nm and emission at λ 302 nm.

10 The IC_{50} of the NCE for CYP2D6 was calculated by the measurement of the percent of inhibition of the formation of the 1'-hydroxybufuralol in presence of the NCE compared to control samples (no NCE) at a known concentration of the NCE.

The percent of inhibition of the formation of the 1'-hydroxybufuralol is calculated as follows:

$$15 \quad \frac{(1'\text{-hydroxybufuralol formed without inhibitor}) - (1'\text{-hydroxybufuralol formed with inhibitor})}{(1'\text{-hydroxybufuralol area formed without inhibitor})} \times 100$$

The IC_{50} is calculated from the percent inhibition of the formation of the 1'-hydroxybufuralol as follows (assuming competitive inhibition):

$$\frac{\text{NCE Concentration} \times (100 - \text{Percent of inhibition})}{\text{Percent of inhibition}}$$


20 The IC_{50} estimation is assumed valid if inhibition is between 20% and 80% (Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. 1999. Fully automated analysis of activities catalyzed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. *Xenobiotica*, 29(1): 53-75).

-96-

Claims

1. A compound of formula I:

5



wherein

A is selected from -O- and -S-;

10

X is selected from C₂-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂;

15

Y is selected from phenyl, naphthyl, dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl;

20

Z is selected from H, OR₃ or F, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl;

25

R₁ and R₂ are each independently H or C₁-C₄ alkyl;

-97-

with the proviso that, when Z is H, then Y may not be optionally substituted phenyl or optionally substituted naphthyl.

and pharmaceutically acceptable salts thereof.

5

2. A compound as claimed in claim 1, wherein A is -O-.


3. A compound as claimed in claim 1, wherein A is -S-.

10 4. A compound as claimed in any one of the preceding claims, wherein one of R₁ and R₂ is H.

5. A compounds as claimed in any one of the preceding claims, wherein one of R₁ and R₂ is H and the other is methyl.


15

6. A compound as claimed in any one of the preceding claims, wherein the compound possesses the stereochemistry defined in formula II



20

7. A compound as claimed in any one of claims 1 - 5, wherein the compound possesses the stereochemistry defined in formula III



- 98 -

8. A compound as claimed in any one of the preceding claims wherein Z is H.
9. A compound as claimed in any one of the preceding claims, wherein X is C₂-C₈
5 alkyl which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂.
10. A compound as claimed in claim 9 wherein X is selected from ethyl, n-propyl, i-
10 propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, neopentyl, 3,3-dimethylbutyl and 2-ethylbutyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy and -CF₃.
11. A compound as claimed in claim 10 wherein X is selected from n-propyl, i-propyl,
15 n-butyl and i-butyl.
12. A compound as claimed in any one of claims 1 to 8, wherein X is C₂-C₈ alkenyl which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -
20 CN and -CONH₂.
13. A compound as claimed in claim 12 wherein X is 2-methyl-2-propenyl.
14. A compound as claimed in any one of claims 1 to 8, wherein X is C₄-C₈
25 cycloalkylalkyl which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂.
15. A compound as claimed in claim 14 wherein X is selected from cyclohexylmethyl
30 and cyclopropylmethyl.

-99-

16. A compound as claimed in any one of the preceding claims, wherein Y is phenyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S-, -CF₃, and -SCF₃.
- 5 17. A compound as claimed in claim 16, wherein Y is phenyl optionally substituted with up to 2 substituents each independently selected from F, Cl, Br, I, Me, Et, OMe, SMe, -CF₃, and -SCF₃.
- 10 18. A compound as claimed in any one of claims 1-15, wherein Y is naphthyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.
- 15 19. A compound as claimed in claim 18, wherein Y is unsubstituted naphthyl or naphthyl which is mono-substituted with a substituent selected from halo, C₁-C₄ alkyl and -CF₃.
- 20 20. A compound as claimed in claim 19 wherein the substituent is located at the 4-position of the naphthyl ring.
21. A compound as claimed in any one of claims 18-20, wherein the point of attachment of the optionally substituted naphthyl group to the -O- or -S- atom is attachment at the 1 position.
- 25 22. A compound as claimed in any one of the claims 1-15, wherein Y is benzofuranyl, benzothiazolyl, benzoisothiazolyl or indolyl each of which may be optionally substituted with up to 4 or, where possible, 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an
- 30 N-substituent selected from C₁-C₄ alkyl.

-100-

23. A compound as claimed in claim 22, wherein Y is benzofuranyl, benzoisothiazolyl or indolyl each of which may be optionally mono-substituted with Me; and when Y is indolyl it may be substituted or further substituted by an N-methyl substituent.
- 5 24. A compound as claimed in any one of claims 22-23, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 7 position.
25. A compound as claimed in any one of claims 22-23, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 4 position.
- 10 26. A compound as claimed in any one of the claims 1-15, wherein Y is benzothienyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.
- 15 27. A compound as claimed in claim 26, wherein Y is benzothienyl optionally substituted with up to 2 substituents each independently selected from halo, C₁-C₄ alkyl, -CF₃ and cyano.
- 20 28. A compound as claimed in any one of claims 26-27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 7 position.
29. A compound as claimed in any one of claims 26-27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 4 position.
- 25 30. A compound as claimed in any one of claims 26-27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 5 position.
31. A compound as claimed in any one of claims 26-27, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 6 position.
- 30

-101-

32. A compound as claimed in any one of the claims 1-15, wherein Y is quinolyl or isoquinolyl each of which may be optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

5

33. A compound as claimed in claim 32, wherein Y is quinolyl or isoquinolyl each of which may be optionally mono-substituted with a halogen atom.

34. A compound as claimed in claim 32 or 33, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 8 position.

10

35. A compound as claimed in claim 32 or 33, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 5 position.

36. A compound as claimed in any one of the claims 1-15, wherein Y is thienopyridyl which may be optionally substituted with up to 4 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

15

37. A compound as claimed in claim 36, wherein Y is unsubstituted thieno-[2,3-b]pyridyl or unsubstituted thieno-[2,3-c]pyridyl.

20

38. A compound as claimed in claim 36 or 37, wherein the point of attachment of the group Y to the -O- or -S- atom is attachment at the 7 position.

25

39. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38, together with a pharmaceutically acceptable diluent or carrier.

40. A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38, for use as a pharmaceutical.

30

-102-

41. A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38, for use as a selective inhibitor of the reuptake of both serotonin and norepinephrine.

5 42. A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38, for use in the treatment of a disorder associated with serotonin and norepinephrine dysfunction in mammals.

10 43. A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38, for use in the treatment of a disorder selected from selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flashes/flushes and pain.

- 15 44. The use of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38, in the manufacture of a medicament for selectively inhibiting the reuptake of serotonin and norepinephrine.

20 45. The use of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38, in the manufacture of a medicament for the treatment of a disorder associated with serotonin and norepinephrine dysfunction in mammals.

25 46. The use as claimed in claim 45, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flashes/flushes and pain.

47. The use as claimed in claim 46, wherein the disorder is selected from depression, urinary incontinence and pain.

30 48. The use as claimed in any one of claims 47, wherein the disorder is pain.

-103-

49. A method for selectively inhibiting the reuptake of serotonin and norepinephrine in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38.

5

50. A method for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in any one of claims 1-38.

10

51. A method as claimed in claim 50, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flashes/flushes and pain.

15 52. A method as claimed in claim 51, wherein the disorder is pain.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/31514

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07C217/64 C07D333/56 A61P25/24 A61P25/18 A61P25/06
A61K31/381 A61K31/137

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	T.L. LEMKE: "beta-Adrenergic blocking agents. alpha- and gamma-Methyl(aryloxy)propanolamines" J.MED.CHEM., vol. 24, no. 10, 1981, pages 1211-1214, XP002275394 *p. 1221, compounds 5a-f*	1,2,4, 16,17, 39-43
X	DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; 30 November 1988 (1988-11-30), XP002275395 Database accession no. BRN: 1463192 AND 1468893 abstract -/-	1,2,8, 32,33, 40-43



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the International filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

30 March 2004

Date of mailing of the international search report

16/04/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Österle, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 03/31514

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	& MNDZHOYAN ET AL: IZV.AKAD.NAUK.ARM.SSR.KHIM.NAUKI, vol. 15, 1962, page 185, -----	
Y	EP 0 373 836 A (LILLY CO ELI) 20 June 1990 (1990-06-20) the whole document	1-17, 26-31, 39-52
Y	US 5 776 969 A (JAMES STEVEN PARKER) 7 July 1998 (1998-07-07) the whole document	1-17, 26-31, 39-52
Y	US 5 023 269 A (ROBERTSON DAVID W ET AL) 11 June 1991 (1991-06-11) the whole document	1-17, 26-31, 39-52
P,X	WO 02/094262 A (RATHMELL RICHARD EDMUND ; FAGAN MARIA ANN (GB); GALLAGHER PETER THADDE) 28 November 2002 (2002-11-28) cited in the application the whole document	1-17, 26-31, 39-52
A	EP 0 814 084 A (LILLY CO ELI) 29 December 1997 (1997-12-29) the whole document	1-17, 26-31, 39-52
A	US 4 229 449 A (MELLONI PIERO ET AL) 21 October 1980 (1980-10-21) cited in the application the whole document -----	1-17, 26-31, 39-52

Form PCT/ISA/210 (continuation of second sheet) (January 2004)

Continuation of Box I.1

Although claims 49-52 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 1-15 (in part), 18-25, 32-38 and 39-52 (in part)

Present claims 1-52 relate to an extremely large number of possible compounds/compositions/methods. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds/compositions/methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds/compositions/methods supported by examples, e.g. compounds in which Y=unsubstituted or substituted phenyl or benzothienyl.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/31514

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 49-52 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-15 (in part), 18-25, 32-38 and 39-52 (in part)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; It is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/31514

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0373836	A	20-06-1990	US	4902710 A		20-02-1990
			AT	102920 T		15-04-1994
			CA	2005173 A1		14-06-1990
			DE	68913930 D1		21-04-1994
			DE	68913930 T2		14-07-1994
			EP	0373836 A1		20-06-1990
			JP	2218661 A		31-08-1990
US 5776969	A	07-07-1998	NONE			
US 5023269	A	11-06-1991	US	4956388 A		11-09-1990
			AT	57924 T		15-11-1990
			AU	591007 B2		23-11-1989
			AU	8266087 A		23-06-1988
			CA	1302421 C		02-06-1992
			CN	87108175 A ,B		06-07-1988
			CY	1682 A		10-10-1993
			DE	3765919 D1		06-12-1990
			DK	664887 A		23-06-1988
			EG	18230 A		30-10-1992
			EP	0273658 A1		06-07-1988
			GR	3001207 T3		30-07-1992
			HK	69693 A		30-07-1993
			HU	47561 A2		28-03-1989
			IL	84863 A		29-03-1992
			JP	2549681 B2		30-10-1996
			JP	63185946 A		01-08-1988
			KR	9603808 B1		22-03-1996
			MX	9845 A		01-12-1993
			NZ	222980 A		28-11-1989
			PH	26556 A		19-08-1992
			PT	86389 A ,B		01-01-1988
			SG	114992 G		29-01-1993
			SU	1598865 A3		07-10-1990
			ZA	8709472 A		30-08-1989
WO 02094262	A	28-11-2002	CA	2445010 A1		28-11-2002
			EP	1397129 A1		17-03-2004
			WO	02094262 A1		28-11-2002
EP 0814084	A	29-12-1997	AT	203990 T		15-08-2001
			AU	3401797 A		07-01-1998
			CA	2257962 A1		24-12-1997
			DE	69706000 D1		13-09-2001
			DE	69706000 T2		04-04-2002
			DK	814084 T3		08-10-2001
			EP	0814084 A1		29-12-1997
			ES	2160894 T3		16-11-2001
			GR	3037072 T3		31-01-2002
			HK	1008525 A1		15-03-2002
			JP	2000513358 T		10-10-2000
			PT	814084 T		30-11-2001
			WO	9748698 A1		24-12-1997
			US	5912256 A		15-06-1999
US 4229449	A	21-10-1980	IT	1111676 B		13-01-1986
			IT	1160301 B		11-03-1987
			IT	1160302 B		11-03-1987

Form PCT/ISA/210 (patent family annex) (January 2004)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/31514

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4229449	A	IT 1101724 B	07-10-1985
		AT 371813 B	10-08-1983
		AT 40679 A	15-12-1982
		AU 525954 B2	09-12-1982
		AU 4332779 A	26-07-1979
		BE 873596 A1	19-07-1979
		BG 61056 B2	30-09-1996
		CA 1128942 A1	03-08-1982
		CH 650245 A5	15-07-1985
		CS 207696 B2	31-08-1981
		CS 9104133 A3	13-05-1992
		CY 1172 A	10-06-1983
		DE 2901032 A1	02-08-1979
		DK 22679 A ,B,	21-07-1979
		FI 790177 A ,B,	21-07-1979
		FR 2442839 A1	27-06-1980
		FR 2430412 A1	01-02-1980
		GB 2014981 A ,B	05-09-1979
		HK 5783 A	08-02-1983
		IE 47727 B1	30-05-1984
		IL 56369 A	31-05-1984
		JP 1504458 C	28-06-1989
		JP 54148739 A	21-11-1979
		JP 63031455 B	23-06-1988
		KE 3243 A	03-12-1982
		MY 1884 A	31-12-1984
		NL 7900412 A ,B,	24-07-1979
		NO 790205 A ,B,	23-07-1979
		NZ 189418 A	16-03-1981
		SE 446727 B	06-10-1986
		SE 7900498 A	21-07-1979
		SI 7910096 A8	31-10-1996
		US 4271160 A	02-06-1981
		YU 9679 A1	31-12-1983
		ZA 7900215 A	26-03-1980
		AT 376964 B	25-01-1985
		AT 419781 A	15-06-1984
		CS 207697 B2	31-08-1981
		MX 9203112 A1	01-07-1992
		SU 980617 A3	07-12-1982
		HU 178214 B	28-03-1982
		SU 944500 A3	15-07-1982